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A B S T R A C T
Background
Mass treatment with albendazole co-administered with another antifilarial drug is part of a global programme to eliminate lymphatic
filariasis. We sought reliable evidence of the effects of albendazole on the disease and the parasite.
Objectives
To summarize the effects of albendazole alone or in combination with antifilarial drugs for clinical treatment and community control
of lymphatic filariasis.
Search strategy
We searched the Cochrane Infectious Diseases Group Specialized Register (August 2005), CENTRAL (The Cochrane Library Issue 3,
2005), MEDLINE (1966 to August 2005), EMBASE (1974 to August 2005), LILACS (1982 to August 2005), and reference lists. We
also contacted researchers, the World Health Organization, and GlaxoSmithKline.
Selection criteria
Randomized and quasi-randomized controlled trials of albendazole alone or combined with another antifilarial drug for treating
individuals with lymphatic filariasis, or for reducing transmission in endemic communities.
Data collection and analysis
Two authors independently assessed eligibility and trial quality, and extracted data. Authors contacted investigators for missing infor-
mation or clarification.
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Main results
Seven trials including 6997 participants (995 with detectable microfilariae) met the criteria. A comparison of albendazole and placebo
detected no effect on microfilariae prevalence (920 participants; 3 trials); one trial (499 participants) reported significantly lower
microfilariae density at six months. Albendazole performed slightly worse than ivermectin in two trials (436 participants). Compared
with diethylcarbamazine (DEC), two small trials (56 participants) found little difference in microfilariae prevalence over an extended
follow up. One larger trial (502 participants) found a statistically significant effect for DEC at six months, but none at three months.
Microfilariae prevalence and density were statistically significantly lower with the combination of albendazole and ivermectin compared
with ivermectin alone in two of three trials (649 participants). Two trials compared albendazole plus DEC with DEC alone and found
no statistically significant difference in microfilariae prevalence, though one trial favoured the combination at six months (risk ratio
0.62, 95% confidence interval 0.32 to 1.21; 491 participants). This trial also found a statistically significant reduction in microfilariae
density.
Authors’ conclusions
There is insufficient evidence to confirm or refute that albendazole co-administered with DEC or ivermectin is more effective than
DEC or ivermectin alone in clearing microfilariae or killing adult worms. Albendazole combined with ivermectin appears to have a
small effect on microfilaraemia, but this was not consistently demonstrated. The effect of albendazole against adult and larval filarial
parasites, alone and in combination with other antifilarial drugs, deserves further rigorous research.
P L A I N L A N G U A G E S U M M A R Y
Not enough evidence on effectiveness of the drug albendazole, alone or in combination, for killing or interrupting transmission
of threadlike worms that cause lymphatic filariasis
Filariasis affects about 120 million people in more than 80 countries and is spread by mosquitoes. Adult worms take up residence in
lymph channels and when paired, produce larvae that circulate in the blood. The adult worms can live in the lymph system for five
years or more. The infection can cause severe disability, due to massive enlargement of limbs, genitals, and breasts. On the other hand,
many infected people have no symptoms, but do contribute to the perpetuation of the infection in the community. This review of trials
found insufficient evidence to say whether a single dose of the drug albendazole kills the worms, or whether, if given in combination
with diethylcarbamazine or ivermectin, it enhances the killing of these worms or the larvae they produce.
B A C K G R O U N D
Epidemiology
Lymphatic filariasis is a parasitic infection of threadlike, filarial
worms that affects about 120millionpeople inmore than 80 coun-
tries (Michael 1996; WHO 2000). Bancroftian filariasis, caused
by infection with Wuchereria bancrofti, occurs in tropical regions
of Asia, Africa, China, and the Pacific islands, and in parts of the
Caribbean and South America. Brugian filariasis is less common,
with Brugia malayi occurring in parts of Asia, and Brugia timori
in Indonesia (FGN 1996).
Filariasis is transmitted by mosquitoes from a number of genera
(including Culex, Anopheles, Mansonia, Ochlerotatus, and Aedes)
(Burkot 2002). Female mosquitoes transmit the disease. They are
infected when they take blood meals from people with microfilar-
iae (mf), early stage larvae. The larvae develop for about 12 to 15
days in the mosquito to a mature larval stage (Scott 2000). When
the mosquito takes a subsequent blood meal, the larvae enter the
skin, migrate to the lymph vessels, and develop into adult worms,
where male and female worms pair. They later produce mf, which
migrate to the blood causing microfilaraemia. The time between
being infected and adult worms producing microfilaraemia is es-
timated to be about 12 months (Mahoney 1971).
Microfilariae move in and out of circulating peripheral blood ac-
cording to a daily cycle. In most species, mf levels peak during
the night, between 10 pm to 4 am (Simonsen 1997), a time when
mosquito vectors are actively feeding. In Fiji, Polynesia, and the
Philippines some strains of Wuchereria bancrofti mf peak during
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the day (Scott 2000).
Clinical features
Many people with filariasis may be asymptomatic most of the
time. However, even people without clinical symptoms often have
lymphatic changes, including lymphangiectasia (widening of the
lymphatic vessels) and thickening of the spermatic cord (Addiss
2000; Dreyer 2000), which can be detected through imaging stud-
ies. Clinical symptoms and signs include hydrocoele (excess fluid
inside the scrotal sac), lymphoedema (swelling and enlargement
of affected areas of the body), and elephantiasis (long standing en-
largement and swelling of the limbs, scrota, or breasts associated
with skin thickening).
Historically, filarial infection has been diagnosed by examining a
blood smear for mf, but, even if blood is taken at night, not all
infections are detected because mf levels are very low in many
people. Antigen assays, which became available for field use during
the 1990s, are more sensitive and can be used for blood collected
during the day or night (Weil 1997) because they indicate the
presence of the adult worm and do not depend on the temporal
presence of mf. Ultrasound imaging can demonstrate the presence
of live adult worms (Dreyer 1995).
How the filarial worm causes disease is not well understood. The
followinghave beenproposed: adultworms living in anddamaging
lymph vessels; immunologic reactions to the presence and death of
filarial worms; secondary infections of affected areas, which con-
tribute significantly to both acute and chronic disease manifesta-
tions (Dreyer 2000). Researchers have also suggested that toxins
released by Wolbachia (endosymbiotic bacteria found within the
cells of filarial worms) cause disease (Taylor 2001). Some or all of
these processes may be important.
Control
Control strategies aim to reduce mf in the community to levels
that prevent transmission (Ottesen 1997; Ottesen 1999). Treat-
ment of individuals with clinical disease is generally only partially
effective (at least in part because there is no drug that reliably kills
the ’macrofilariae’, the adult worms). Mass drug administration
programmes therefore aim for a sustainable reduction in com-
munity mf loads below a critical threshold or a complete clear-
ance of mf to have an appreciable impact on transmission. The
Global Programme toEliminate Lymphatic Filariasis recommends
yearly, single-dose, two-drug regimens (albendazole plus diethyl-
carbamazine or albendazole plus ivermectin) for at least five years
(corresponding to the reproductive lifespan of the adult worm) to
prevent transmission. However, the critical threshold below which
no further transmission will take place is unclear and may depend
on the vector species in the locality. Some mosquitoes (eg Aedes
polynesiensis, some culicine mosquitoes in India and the Americas)
may be more efficient at lower mf densities (a process known as
limitation). Higher treatment coverage for longer periods or other
strategies such as vector control may be required in areas where
these vectors are responsible for a high proportion of transmission
(Burkot 2002; Pichon 2002).
Ivermectin and diethylcarbamazine (DEC) both kill mf. DEC
may have some temporary sterilizing effects or actually kill adult
worms, so one treatment with either drug can affect mf levels for
many months. Reductions of 90% from pretreatment mf levels
have been seen after a single dose of DEC or ivermectin even one
year after treatment (Ottesen1999). The impact of drug treatment
on transmission can be enhanced, if currently available antifilarial
drugs demonstrate a killing or sterilizing effect on adult worms,
in addition to their effect on mf. There are concerns that an over
reliance on a limited range of drugs may eventually cause resis-
tance, although there is little direct evidence that this is currently
a problem in filariasis (Barat 1997; Geerts 2001).
It has been observed that some infected people lose their mf in
the absence of treatment (Vanamail 1990). However, overall mf
prevalence rates are believed to be relatively stable over time in
endemic communities in the absence of community treatment
(Meyrowitsch 1995); newmicrofilaraemic infections replace those
whosemicrofilaraemia subsides (Vanamail 1990;Weil 1999).Nev-
ertheless, lymphatic filariasis has been eradicated using vector con-
trol methods from some areas such as the Solomon Islands, Aus-
tralia (Burkot 2002; Pichon 2002), and parts of China usingDEC-
fortified salt and other DEC regimens (Gelband 1994).
DEC and ivermectin
DEC has been in use for filariasis for more than 50 years. In the
early years of control the recommended regimen for DEC was 6
mg/kg daily for 12 days (WHO 1984). Later, clinical and com-
munity trials determined that single doses given at various inter-
vals − weekly, monthly, annually, and biannually − were equally
effective (Andrade 1995; Eberhard 1989; Simonsen 1995). There
is reasonable evidence from ultrasound and clinical observations
that DEC kills some adult worms (macrofilariae) after single doses
(Addiss 2000; Figueredo-Silva 1996; Noroes 1997).
Ivermectin is used for the treatment and community control of
onchocerciasis (caused by another filarial worm,Onchocerca volvu-
lus). It has also been effective in community control programs for
lymphatic filariasis (Cao 1997; Cartel 1990; Coutinho 1994). It
can be used in many places, but it is particularly important in
areas where both onchocerciasis and lymphatic filariasis coexist
because DEC can cause eye damage if given to individuals with
onchocerciasis. However, recent ultrasound studies suggest that
adult worms are not killed by ivermectin, even at high doses over
a period of six months (Addiss 2000; Dreyer 1996).
Adverse effects of antifilarial drugs can be serious (though almost
never fatal) and prevent people from completing treatment. The
most serious appear to be due to a host immunologic reaction to
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the dying worms (Dreyer 1994; WHO 1984). These effects in-
clude fever, headache, malaise, muscle pain, and blood in urine.
Local effects include localized pain, tender nodules, lymphadenitis
(inflammation of the lymph nodes), and lymphangitis (inflamma-
tion of lymph vessels) (Addiss 2000).
Albendazole
Albendazole has been used widely to treat intestinal parasites since
the late 1980s and may have a potential role in lymphatic filar-
iasis control (Ottesen 1999). A report from an informal consul-
tation organised by the World Health Organization suggests that
repeated high doses of albendazole have a killing or sterilizing
effect on W. bancrofti adult worms (CDS/FIL 1998). However,
the data in the report are scanty and it remains unclear whether
adding albendazole to either DEC or ivermectin improves cure,
prevents further transmission, or influences the occurrence of ad-
verse events. A narrative review by Horton 2000 from Glaxo-
SmithKline, which manufactures albendazole, did not demon-
strate that adding albendazole to either drug increased the fre-
quency or severity of adverse events. GlaxoSmithKline states that
albendazole does not have a role in morbidity management − it
will not treat the symptoms in people already affected by filaria-
sis (GlaxoSmithKline 2003). But at least one trial has considered
the effectiveness of albendazole in reducing both disease progres-
sion and incidence of new symptoms (such as hydrocoele) (Dunyo
2000). We therefore include this as a secondary outcome.
A recently published review concluded that co-administration of
albendazole was more effective in reducing mf prevalence than one
antifilarial drug alone (Gyapong 2005). This review had included
observational data and did not assess the quality of the studies,
whilst our analysis included only higher quality randomized con-
trolled trials. Most importantly, Gyapong 2005 incorporated data
from several studies twice (by counting results at six and twelve
months and combining them in the same meta-analysis), which
artificially narrows the 95% confidence intervals. This resulted in
the authors erroneously concluding that overall the effect was ’sta-
tistically significant’ (Gyapong 2005).
In this review, we aim to summarize the evidence for the effects
of albendazole alone or in combination with DEC or ivermectin
in both the individual treatment and transmission control of lym-
phatic filariasis.
O B J E C T I V E S
1. To assess the effects of albendazole on individuals or
populations with filarial infection.
2. To assess the effects of albendazole on morbidity among
individuals with filarial infection (incidence of new disease or
progression of existing symptoms).
3. To assess the frequency of adverse events for albendazole
both given singly or in combination with another antifilarial
drug (DEC or ivermectin).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials; cluster-randomized controlled tri-
als; and quasi-randomized controlled trials.
Types of participants
• Adults or children with filarial infection defined by the
presence of mf parasites in the blood, filarial antigens in the
blood, or ultrasound detection of adult worms in lymphatic
vessels.
• Populations normally resident in endemic communities and
who are eligible for treatment regardless of microfilaraemia status
(community trials).
Types of interventions
• Albendazole alone versus placebo.
• Albendazole alone versus DEC.
• Albendazole alone versus ivermectin.
• Albendazole plus DEC versus DEC (DEC dose and
regimen same in both arms).
• Albendazole plus ivermectin versus ivermectin (ivermectin
dose and regimen same in both arms).
Types of outcome measures
Primary
• Mf prevalence.
• Mf density.
• Community mf density (in mass treatment trials).
• Antigenaemia prevalence or density.
• Adult worms (macrofilariae viability detected by
ultrasound).
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Secondary
• Acute filariasis (fever plus clinical evidence of inflammation
of the lymphatic system, as defined by primary investigators).
• Appearance or disappearance of hydrocoele or
lymphoedema.
• Reduction in size (or severity or grade) of hydrocoele or
lymphoedema.
Adverse events
• Adverse events that prevent daily activities or require
hospitalization.
• Systemic adverse events (eg fever, headache, malaise,
myalgia, or haematuria).
• Local adverse events (eg localized pain and inflammation,
tender nodules, lymphadenitis, or lymphangitis).
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Databases
We searched the following databases using the search terms and
strategy described in Appendix 1: Cochrane Infectious Diseases
Group SpecializedRegister (August 2005); CochraneCentral Reg-
ister of Controlled Trials (CENTRAL), published inTheCochrane
Library (Issue 3, 2005); MEDLINE (1966 to August 2005); EM-
BASE (1974 to August 2005); and LILACS (1982 to August
2005).
Researchers, organizations, and pharmaceutical
companies
We contacted individual researchers working in the field, the
World Health Organization, and GlaxoSmithKline (the company
producing albendazole) for unpublished and ongoing trials.
Reference lists
We also checked the reference lists of all studies identified by the
above methods.
Data collection and analysis
Selection of studies
One author (Henry Ejere (HE) or Julia Critchley (JC)) screened
titles and abstracts identified from the search strategy. Hard copies
of the published or unpublished trial reports potentially relevant to
the review were retrieved for further assessment. Two authors (HE
or JC and Paul Garner (PG)) independently used a predesigned
eligibility form to select trials that met the inclusion criteria. Dis-
agreements were resolved through discussion.
Data extraction and management
One author (HE or JC) extracted data, which a second author
(PG) checked. Where trials reported the same outcomes in differ-
ent ways, we attempted to contact the primary investigators for
further information, which might allow transformation of data.
We extracted data relating to trial and participant characteristics,
and reported outcomemeasures. We intended to extract data to al-
low an intention-to-treat analysis (all the participants analysed ac-
cording to the intervention towhich theywere originally allocated,
whether they received it or not). This was not possible, but may
be attempted in future updates. Where the numbers randomized
and the numbers analysed for each outcome were inconsistent, we
calculated the percentage loss to follow up and recorded this infor-
mation in Appendix 2. For dichotomous outcomes, we recorded
the number of participants experiencing the event in each group of
the trial. For continuous outcomes, we extracted arithmetic means
and standard deviations. Where geometric means were reported,
we extracted and recorded this information. We also tried to ex-
tract confidence intervals or standard deviations on the log scale.
One author (HE or JC) entered data into Review Manager 5.
Assessment of risk of bias in included studies
Two authors (HE or JC and PG) independently assessed trials ac-
cording to predefined quality criteria. We assessed the generation
of allocation sequence and concealment of allocation to be ade-
quate, inadequate, or unclear according to Jüni 2001. We assessed
blinding as double blind (trial uses a placebo or a double dummy
technique such that neither the participant or care provider/asses-
sor knows which treatment is given), single blind (participant or
care provider/assessor is aware of the treatment given), or open (all
parties are aware of the treatment). We assessed the inclusion of
all randomized participants in the analysis to be adequate if 90%
or more were included.
Data synthesis
We grouped the trials by the main comparator interventions, such
as albendazole versus placebo.Within comparator groups, we strat-
ified trials into those of treatment in individuals and trials of mass
treatment in communities. Where appropriate we combined trials
in a meta-analysis using a fixed-effect model. We calculated risk
ratios (RR) for dichotomous outcomes and used 95% confidence
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intervals. We reported medians and ranges in tables only. We as-
sessed heterogeneity by visually inspecting forest plots and carry-
ing out a chi-squared test for heterogeneity (statistical significance
at 10% level). We used the random-effects model to pool data
where we detected heterogeneity. Too few trials were available to
examine heterogeneity in any more detail, but this might be pos-
sible in future updates.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Trial selection
We identified 12 published trials of which seven met the inclu-
sion criteria (see ’Characteristics of included studies’).We excluded
five studies reported in eight publications (see ’Characteristics
of excluded studies’). We are aware of one ongoing study (see
’Characteristics of ongoing studies’).
Study design and location
All the trials randomized individual participants. The length of
the follow up varied: four months (Beach 1999); six months (
Fox 2005); 12 months (Dunyo 2000; Kshirsagar 2004; Simonsen
2004); 19 months (Jayakody 1993); and two years (Pani 2002).
The trialswere conducted in southernGhana (Dunyo 2000),Haiti
(Beach 1999; Fox 2005), India (Kshirsagar 2004; Pani 2002), Sri
Lanka (Jayakody 1993), and Tanzania (Simonsen 2004).
Participants
Nine-hundred and ninety five of the 6997 randomized partici-
pants had detectable mf. Jayakody 1993 and Pani 2002 enrolled
people whoweremf positive.Dunyo 2000, Beach 1999, Simonsen
2004, and Fox 2005 enrolled people regardless of mf status at
baseline. Kshirsagar 2004 enrolled 1403 participants for a safety
study and included 103 of these in a separate analysis of efficacy.
Forty-three of the 103 were mf positive, 30 had clinical disease,
and 30 were mf negative and asymptomatic. However, at most
time points, mf prevalence results were only available for the 43
mf-positive participants.
Intervention
The trials addressed all the pre-specified comparisons: albenda-
zole alone versus placebo (Beach 1999; Dunyo 2000; Fox 2005);
albendazole alone versus DEC (Fox 2005; Jayakody 1993; Pani
2002); albendazole alone versus ivermectin (Beach 1999; Dunyo
2000); albendazole plus DEC versus DEC (Fox 2005; Kshirsagar
2004; Pani 2002); and albendazole plus ivermectin versus iver-
mectin (Beach 1999; Dunyo 2000; Simonsen 2004).
All the trials used the same albendazole dose (400 mg). The three
trials using ivermectin had different doses: 200 to 400 µg/kg (
Beach 1999); and 150 to 200 µg/kg (Dunyo 2000; Simonsen
2004). The DEC dose was 6 mg/kg body weight. The drugs were
given as a single treatment in all trials except for Jayakody 1993
in which DEC was given daily and albendazole twice daily for 21
days.
Outcomes
All trials reported on mf. The methods of measurement varied,
including prevalence in 20 µL of blood (Beach 1999), prevalence
and density in 20 µL of blood (Fox 2005), prevalence in 60 µL of
blood (Kshirsagar 2004), prevalence in 1mLof venous blood (Pani
2002), and prevalence in 1 mL blood using membrane filtration (
Jayakody 1993), or prevalence in 100µLusing a counting chamber
(Dunyo 2000; Simonsen 2004); see Appendix 3 and Appendix 5
for mf prevalence and mf density, respectively.
Several trials also reported antigen prevalence or density (Dunyo
2000; Fox 2005; Kshirsagar 2004; Pani 2002; Simonsen 2004);
see Appendix 4 and Appendix 6. Two trials determined the effect
of treatment on adult worms by ultrasound scan for a subgroup
of participants (Kshirsagar 2004; Pani 2002); see Appendix 7.
All trials reported adverse events, but the methods of reporting
varied (see ’Characteristics of included studies’ and Appendix 8).
Reported statistical analysis
Standard deviations or confidence intervals were not reported for
mf density outcomes; this information was obtained from the in-
vestigators for Fox 2005. As so few trials reported standard devia-
tions, we could not pool results for changes in mf density; results
quoted in this review are the original trial author’s calculations.
Two trials, Jayakody 1993 and Pani 2002, did not clearly describe
the method of calculating reductions in geometric mean mf den-
sity, but Pani 2002 provided further details on request. This trial
calculated aWilliam’smean (amodification of the geometric mean
to take into account zero counts) (Basanez 1994) on the pretreat-
ment and post-treatment mf densities. Dunyo 2000 calculated
change in mf density by two methods the Williams mean and by
using an ’area under the curve’ analysis (an average density over
the whole 12 month post-treatment period). Simonsen 2004 cal-
culated a William’s mean and estimated the combined effect over
the one-year follow-up period using repeatedmeasures techniques
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(either ANOVA or generalized estimating equations). Beach 1999
and Fox 2005 calculated the geometric mean mf density reduc-
tion by dividing the difference between densities before and after
treatment by the pretreatment mf density and log transforming
the results. If pretreatment mf density was less than the density
after treatment, the reduction was deemed to be zero. The trialists
performed this adjustment to eliminate the problem of log trans-
forming a negative value, but this method may bias estimates of
treatment effectiveness, as increases in mf density after treatment
are set to zero. For this reason, for Beach 1999, we present the tri-
alists’ results in the text and the percentage change using the group
means in tables. The Fox 2005 trial authors recalculated geometric
mean changes taking into account children where mf density in-
creased post-treatment at our request (although estimates do not
include children newly infected over the course of the trial), and
we report these revised figures.
Risk of bias in included studies
See the ’Characteristics of included studies’ for details andAppendix
2 for a summary.
Generation of allocation sequence
All trials were described as randomized, but Pani 2002 and
Kshirsagar 2004 did not describe a method of randomization, and
Jayakody 1993 only stated that the list was predetermined and
restricted.
Allocation concealment
Beach 1999, Dunyo 2000, Pani 2002, and Simonsen 2004 used
a third party in the allocation process to conceal allocation. Allo-
cation concealment was unclear in the other trials.
Blinding
Five of the trials were double blind (Beach 1999; Dunyo 2000;
Kshirsagar 2004; Pani 2002; Simonsen 2004). The outcome asses-
sors were blinded in Fox 2005, and Jayakody 1993 did not men-
tion blinding.
Inclusion of randomized participants in the analysis
Losses of participants during the follow-up period were significant
in most of the trials. In Dunyo 2000, 1181 (82.9%) of the 1425
participants were re-examined at 12 months; 67 of the 340 mf-
positive participants (20%)were also lost to followup. Beach 1999
excluded 380 of 965 (39%) randomized participants who did not
have both pretreatment and post-treatment blood examinations.
However, there were few losses among the mf positive participants
at baseline (3/113). In Jayakody 1993, six of 16 (37.5%) men
allocated to albendazole and three of 13 (23%) allocated to DEC
were lost to follow up by 15 to 19 months. Pani 2002 reported no
losses to follow up. Fox 2005 reported on 990 of 1292 (24% lost)
originally randomized. Simonsen 2004 analysed 1221 of 1829
(33% lost) randomized. Kshirsagar 2004 included only 103 of
1403 participants in the efficacy analysis (43 of whom were mf
positive, 30 had clinical disease, and 30 were asymptomatic mf
negative).
Effects of interventions
1. Albendazole versus placebo
Mf prevalence: all participants (mf positive or negative at
baseline)
Two trials, Beach 1999 and Fox 2005, did not detect a statistically
significant difference after three to fourmonths (783 participants).
There was also no statistically significant difference in prevalence
in the one trial that reported at sixmonths (Fox 2005). SeeAnalysis
1.1.
Mf prevalence: only participants mf positive at baseline
Beach 1999 found no statistically significant difference in the
prevalence between albendazole (22/29) and placebo (20/29) at
four months. Similarly, Dunyo 2000 found no statistically sig-
nificant difference between albendazole (62/71) and placebo (62/
66) at 12 months. A combined estimate from these two trials also
shows no statistically significant difference (RR 0.97, 95%CI 0.87
to 1.09; 195 participants). See Analysis 1.2.
Antigen prevalence: all participants (mf positive or negative
at baseline)
There were no statistically significant differences in the prevalence
of circulating filarial antigen positivity from two trials (Dunyo
2000; Fox 2005) after six to 12 months (1090 participants). See
Analysis 1.3.
Mf density: all participants (mf positive or negative at
baseline)
Fox 2005 reported a reduction in mf density at three and six
months. The three-month reduction was by 8.2% (from 17.3 to
8.7 mf/20 µL) in the placebo group compared with 22% (from
12.1 to 4.7 mf/20 µL, not significant) in the albendazole group.
At six months, it had reduced by 10.3% (17.3 to 11.2 mf/20 µL)
in the placebo group compared with 34.7% (12.1 to 4.7 mf/20
µL) (P < 0.05) in the albendazole group. See Appendix 5.
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Mf density: only participants mf positive at baseline
Beach 1999 estimated the reduction in geometric mean mf den-
sity at four months − 63.8% (from 14.1 to 5.1 mf/20 µL) in
the albendazole group and 43.0% (from 9.3 to 5.3 mf/20 µL) in
the placebo group; this reduction was not statistically significant.
Dunyo 2000 reported a reduction in the geometric mean mf den-
sity between baseline and 12 months of 68.5% (from 798 to 251
mf/100 µL) in the albendazole group compared with 13% (from
971 to 845 mf/100 µL) in the placebo group, but this was not sta-
tistically significant (P = 0.10). An ’area under the curve’ analysis
from this trial found an 8.4% increase in geometric mean mf den-
sity in the placebo group (from 2536 to 2750 mf/100 µL) and a
19.7% decrease in the albendazole group (from 1535 to 1233 mf/
100 µL); again this was not statistically significant (P = 0.12). This
latter analysis was limited to those with a complete data collection
and a mf density of over 100 mf/mL at baseline. See Appendix 5.
Antigen density: all participants (mf positive or negative at
baseline)
There were no statistically significant differences in the geometric
mean percent reduction in antigen density after six months in the
albendazole group (3.2%) and the placebo group (1.7%) in Fox
2005. See Appendix 6.
Antigen density: only participants mf positive at baseline
Dunyo 2000 reported that the geometric mean mf density of the
circulating filarial antigen unit had increased to 147.5% of the
pretreatment level in the placebo group, but it decreased to 83.1%
of the pretreatment level in the albendazole group; the difference
was not statistically significant (P = 0.11). See Appendix 6.
Clinical disease: new and pre-existing
Twelve months after treatment Dunyo 2000 detected no statisti-
cally significant difference in the development of hydrocoele be-
tween participants in the albendazole group (1/129) and placebo
group (1/126). No new cases of acute filariasis and leg lym-
phoedema were observed. Similarly, there were no statistically
significant differences in the improvement of symptoms in lym-
phoedema between the albendazole group (3/13) and the placebo
group (2/9), or in hydrocoele between the albendazole group (3/
8) and placebo group (5/10). Although we did not detect statis-
tically significant differences, the trials lacked power for clinical
outcomes so clinically important differences cannot be ruled out.
See Analysis 1.4 and Analysis 1.5.
Adverse events
Dunyo 2000 did not detect a statistically significant difference
in systemic adverse events between the albendazole group (31/
336) and the placebo group (33/314). No local or severe ad-
verse events were reported. Fox 2005 reported statistically sig-
nificant reductions in myalgias and cough for albendazole com-
pared with placebo, but no statistically significant differences in
headache, fever, or mean treatment impact score. See Analysis 1.6
and Appendix 8.
2. Albendazole versus ivermectin
Mf prevalence: all participants (mf positive or negative at
baseline)
Beach 1999 did not demonstrate a statistically significant dif-
ference between the albendazole group (22/145) and ivermectin
group (20/150). See Analysis 2.1.
Mf prevalence: only participants mf positive at baseline
Beach 1999 reported mf prevalence at four months of follow up:
22/29 in the albendazole group and 17/28 in the ivermectin group.
Dunyo 2000 also reported this outcome: 62/71 in the albendazole
group and 52/70 in the ivermectin group. Pooling the two trials,
albendazole was slightly poorer in clearing mf, but this only just
reached statistical significance (RR 0.84, 95% CI 0.72 to 0.98;
198 participants). See Analysis 2.2.
Antigen prevalence: all participants (mf positive or negative
at baseline)
Dunyo 2000 reported no statistically significant difference in the
number of participants positive for circulating filarial antigen at
baseline or after 12months for those treatedwith albendazole (105
and 110) or ivermectin (99 and 101). See Analysis 2.3.
Mf density: only participants mf positive at baseline
Beach 1999 reported on the percentage reduction in geometric
mean mf density between baseline and four months follow up.
There was a reduction of 28.7% (14.1 to 5.1 mf/20 µL) for the
albendazole group and of 76.1% (15.5 to 1.5 mf/20 µL) for the
ivermectin group, P = 0.02. Dunyo 2000 measured mean values
at baseline and 12 months follow up, which changed from 798
to 251 mf/100 µL (68.5% reduction) for albendazole and from
640 to 124 mf/100 µL (80.6% reduction) for ivermectin; no sta-
tistical significance test was reported. An ’area under the curve’
analysis from this trial found a 19.7% decrease in the albendazole
group (from 1535 to 1233 mf/100 µL) and a 56.2% decrease in
the ivermectin group (from 1731 to 759 mf/100 µL). This latter
analysis was limited to those with complete data collection and a
mf density of more than 100 mf/mL at baseline. See Appendix 5.
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Antigen density: only participants mf positive at baseline
Dunyo 2000 reported that the geometric mean mf density of the
circulating filarial antigen unit had decreased to 83.1% of the
pretreatment level in the albendazole group and 70.3% in the
ivermectin group (no statistical test applied). See Appendix 6.
Clinical disease
Dunyo 2000 found no statistically significant differences in the
risk of developing hydrocoele (1/129 albendazole and 1/133 iver-
mectin), improvements in lymphoedema (3/13 albendazole and
2/13 ivermectin), and improvements in hydrocoele (3/8 albenda-
zole and 2/9 ivermectin), but sample sizes were small and confi-
dence intervals wide. See Analysis 2.4 and Analysis 2.5.
Adverse events
Dunyo 2000 did not detect a statistically significant difference in
the number of systemic adverse events between the albendazole
group (31/336) and ivermectin group (36/295). See Analysis 2.6.
3. Albendazole plus ivermectin versus ivermectin
Mf prevalence: all participants (mf positive or negative at
baseline)
Beach 1999 estimated a statistically significant 65% reduction in
mf prevalence for the combination (7/151) compared with iver-
mectin alone (20/150). See Analysis 3.1.
Mf prevalence: only participants mf positive at baseline
Beach 1999 reported a 73% reduction inmf at fourmonths for the
combination compared with ivermectin alone (4/24) mf positive
at four months for the combination compared with (17/28) for
ivermectin alone). Simonsen 2004 reported a smaller reduction at
six months (203 participants). Overall, there was no statistically
significant difference at four to six months (RR 0.49, 95%CI 0.18
to 1.39, random-effects model; 255 participants).
Two trials reported on this outcome at 12 months (Dunyo 2000;
Simonsen 2004). Both trials found no statistically significant dif-
ference between the combination and ivermectin (RR 1.00, 95%
CI 0.88 to 1.13; 348 participants). See Analysis 3.2.
Antigen prevalence: all participants (mf positive or negative
at baseline)
Dunyo 2000 reported no statistically significant difference in the
numbers positive for circulating filarial antigen at baseline or 12
months (121 to 122 for albendazole plus ivermectin; 99 to 101
for ivermectin alone). See Analysis 3.3.
Antigen prevalence: only participants antigen positive at
baseline
NeitherDunyo 2000 nor Simonsen 2004 reported any statistically
significant differences at six or 12 months. See Analysis 3.4.
Mf density: only participants mf positive at baseline
Beach 1999 reported a reduction in the geometricmeanmf density
at four months of 98.9% for the combination group compared
with 76.1% for the ivermectin group (P < 0.05).
Dunyo 2000 reported that the reduction in geometric mean mf
density in both groups after 12 months was 87.3% for the combi-
nation and 80.6% for ivermectin, but it was not statistically signif-
icant (P = 0.80). An ’area under the curve’ analysis from this trial
found that the 69.3% decrease in the combination group (from
1280 to 393 mf/100 µL) and the 56.2% decrease in the ivermectin
group (from 1731 to 759 mf/100 µL) was also not statistically
significant (P = 0.26). This latter analysis was limited to those with
complete data collection and a mf density of over 100 mf/mL at
baseline.
Simonsen 2004 reported reductions in the geometric mean mf
density in the ivermectin group of 80.4%at sixmonths and 83.6%
at 12 months. The reductions were greater in the combination
group, 96.3% at six months and 92.6% at 12 months. A repeated
measures ANOVA demonstrated a statistically significantly higher
rate of reduction in the combination group (P < 0.0001). See
Appendix 5.
Antigen density: only participants antigen positive at
baseline
There were no significant differences in the percentage reduction
in antigen density for the combination group (59.3%) compared
with ivermectin (70.3%) (P = 0.8). See Appendix 6.
Clinical disease
Dunyo 2000 found no statistically significant difference in the
number of new cases of hydrocoele between the combination
group (2/147) and the ivermectin group (1/133). This trial also
observed no statistically significant differences in the improvement
of lymphoedema (2/13 in combination group and 2/13 in iver-
mectin group) and hydrocoele (4/10 in combination group and
2/9 in ivermectin group). Again, the trials were not designed to
detect changes in clinical outcomes; therefore confidence intervals
are very wide. See Analysis 3.5 and Analysis 3.6.
Adverse events
Dunyo 2000 recorded more adverse events with the combination
treatment (47/332) compared with ivermectin (36/295), but this
was not statistically significant. See Analysis 3.7 and Appendix 8.
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4. Albendazole versus DEC
Two of the three trials that made this comparison were very small
and recruited only participants who were mf positive at baseline
(Jayakody 1993; Pani 2002). Jayakody 1993 compared albenda-
zole (16 participants) with DEC (13 participants) and attempted
to follow the participants for 19 months. They reported that all
participants in this extended follow up lived nearby and had re-
ceived treatment in addition to the study intervention, but they
did not report the specifics of the additional treatment. Pani 2002
compared albendazole (19 participants) DEC (17 participants),
and albendazole plusDEC co-administered (18 participants). The
third trial, Fox 2005, was larger and included children irrespective
of mf status from an endemic community.
Mf prevalence: all participants (mf positive or negative at
baseline)
Fox 2005 found no statistically significant difference at three
months, but there was a statistically significant difference in favour
of DEC at six months (RR 1.74, 95% CI 1.05 to 2.88; 502 par-
ticipants). See Analysis 4.1.
Mf prevalence: only participants mf positive at baseline
Pani 2002 reported no statistically significant difference at 90 days
or 360 days for albendazole (5/19) or DEC (3/17). Jayakody
1993 stated that 85% (numerator and denominator unclear) of
the albendazole-treated participants and 67% (8/12) of the DEC-
treated participants still had detectable mf at six months. After
15 to 19 months, 50% (5/10 for both groups) of participants in
both groups were mf positive, but a substantial proportion of the
participants had been lost during this follow-up period. Pani 2002
continued to follow the participants for up to two years, but they
found no statistically significant difference in mf prevalence at this
time. See Analysis 4.2.
Antigen prevalence: all participants (mf positive or negative
at baseline)
Fox 2005 found no statistically significant difference in antigen
prevalence at six months. See Analysis 4.3.
Antigen prevalence: only participants mf positive at baseline
Pani 2002 reported no statistically significant difference in the
prevalence of filarial antigenaemia at any point during the trial (P
> 0.05). The percentage reduction measured using immunochro-
matographic test (ICT) was 83% with albendazole and 87% with
DEC; using Og4C3, it was 83% with albendazole and 80% with
DEC. See Analysis 4.4.
Mf density: all participants (mf positive or negative at
baseline)
Fox 2005 reported a fall in the geometric mean mf density in
both groups from baseline to three months to six months. The
percentage reduction at six months was 34.7% for the albendazole
group and 50.4% for the DEC group, but this difference was not
statistically significant. See Appendix 5.
Mf density: only participants mf positive at baseline
Pani 2002 reported no statistically significant difference in per-
centage reductions in geometric mean mf density at any of the
time points this was measured (days 3, 7, and 360). The mf den-
sity appeared to fall faster during the first seven days with DEC
compared with albendazole.
Jayakody 1993 also found large reductions in geometric mean
mf density at six months for both treatment groups: 1.9% of its
initial value for those treatedwith albendazole and 0.81% for those
treated with DEC. After 15 to 19 months of follow up there was
no statistically significant difference (geometric mean mf density
3 mf/mL for albendazole and 2 mf/mL for DEC). Similarly to
Pani 2002, the mf density appeared to fall faster during the first
28 days with DEC compared with albendazole. See Appendix 5.
Antigen density: all participants (mf positive or negative at
baseline)
Fox 2005 reported that after six months the geometric mean anti-
gen density was reduced by 17% in the DEC group compared
with 3.2% in the albendazole group (P < 0.05). See Appendix 6.
Antigen density: participants mf positive at baseline
Pani 2002 found statistically significant reductions inmean optical
antigen density by Og4C3 assay in both groups at 360 days: 0.41
with albendazole (P < 0.0001) and 0.32 with DEC (P < 0.0001).
See Appendix 6.
Adult worms
Pani 2002 reported no statistically significant differences in detec-
tion of adult worms by ultrasonography at one or two years, but
only a small number of participants were included in this analysis.
See Appendix 7.
Adverse events
Pani 2002 reportedno life-threatening adverse events in any group.
Those observed were transient (not lasting beyond six days) and
included fever, myalgia, and headache. There was no statistically
significant difference in the proportion reporting any systemic ad-
verse events between albendazole (8/19) and DEC (9/17). The
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mean score of adverse reaction intensity was lower for albendazole
compared with DEC (P < 0.05), but the validity and clinical sig-
nificance of this scoring system was uncertain.
Jayakody 1993 reported that 11of 15participants receiving the full
treatment regimen for albendazole developed ’scrotal syndrome’,
which was classified as ’severe’ for two men, moderate for two, and
mild for the other seven. None of the participants on DEC devel-
oped similar symptoms. One participant on DEC had fever, right
hypochondrial pain, and repeated vomiting, and was withdrawn
from the trial. Drug doses were much higher in this trial than in
the other three. Participants were given albendazole twice a day or
DEC once a day for three weeks unlike the other trials that tested
a single dose of albendazole plus DEC or ivermectin.
Fox 2005 reported more myalgias in the DEC group (8/44) than
the albendazole group (1/46) (P < 0.05), and a higher treatment
impact score at days one and two (P<0.05), but therewere noother
statistically significant differences between the treatment groups.
See Analysis 4.5 and Analysis 4.6, and Appendix 8.
5. Albendazole plus DEC versus DEC
Mf prevalence: all participants (mf positive or negative at
baseline)
Fox 2005 showed no statistically significant difference inmf preva-
lence at three months or six months. See Analysis 5.1.
Mf prevalence: only participants mf positive at baseline
The two trials from India, Kshirsagar 2004 and Pani 2002, re-
ported mf prevalence at various time points between three months
and two years. There were no statistically significant differences at
any time point. See Analysis 5.2.
Antigen prevalence: all participants (mf positive or negative
at baseline)
Two trials, Fox 2005 and Kshirsagar 2004, showed no statisti-
cally significant difference in antigen prevalence at either six or 12
months. See Analysis 5.3 and Appendix 4.
Antigen prevalence: only participants antigen positive at
baseline
Pani 2002 reported no statistically significant difference in preva-
lence of filarial antigenaemia by at any point during the trial (P
> 0.05). The percentage reduction after one year was 75% on al-
bendazole plus DEC compared with 87% on DEC, as measured
by immunochromatographic test (ICT), and 81% on albendazole
and DEC compared with 80% on DEC, as measured by Og4C3.
See Analysis 5.4 and Appendix 4.
Mf density: all participants (mf positive or negative at
baseline)
Fox 2005 reported similar geometric mean percent reductions in
mf density at threemonths, but at sixmonths theywere statistically
significantly greater in the combination arm (80.4% compared
with 50.4%, P < 0.05). See Appendix 5.
Mf density: only participants mf positive at baseline
Pani 2002 reported no statistically significant difference in per-
centage reductions in the geometricmeanmf density. SeeAppendix
5.
Antigen density: all participants (mf positive or negative) at
baseline
After six months, the geometric mean reduction in antigen density
was greater in the combination arm (26.7%) than the DEC arm
(17.0%), but the difference was not statistically significant (Fox
2005). See Appendix 6.
Antigen density: only participants mf positive at baseline
Pani 2002 reported statistically significant reductions in mean op-
tical antigen density by Og4C3 assay in both groups at 360 days
compared with the pretreatment value: a reduction of 0.40 with
albendazole plus DEC (P < 0.0001) and 0.32 with DEC (P <
0.0001). There were no differences in the reduction in antigen
density between the combination and DEC group. See Appendix
6.
Adult worms
There were no statistically significant differences in detection of
adult worms by ultrasonography in Pani 2002 or Kshirsagar 2004,
but only a small number of participants were included in this
analysis. See Appendix 7.
Adverse events
Pani 2002 reported no statistically significant difference in the
proportion reporting any systemic adverse events (11/18 for al-
bendazole plus DEC and 9/17 for DEC) or in the mean score of
adverse reaction intensity (6.7 (sd 6.6) for albendazole plus DEC
and 5.6 (sd 7.1) for DEC).
Fox 2005 found no statistically significant differences in specific
symptoms or treatment impact scores for the combination com-
pared with DEC alone.
Kshirsagar 2004 assessed adverse drug events in a large sample size
(1403 participants). There were no statistically significant differ-
ences in the proportion of participants reporting an adverse drug
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reaction by day seven in the DEC group compared with the com-
bination group (128/693 versus 120/702) ), or the proportions ex-
periencing adverse events that interfered with daily activities (29/
694, 4.2% and 31/702, 4.4% respectively). The adverse events
generally appeared mild in both arms, with no life-threatening or
disabling events (Common Toxicity Criteria grade 4) reported;
most were mild or moderate adverse events. See Analysis 5.5 and
Appendix 8.
D I S C U S S I O N
This review was designed to assess the effects of albendazole alone
or in combination with the currently recommended antifilarial
drugs, ivermectin or DEC. Although the review has considered
the effects of albendazole alone, the main interest and strategy
of the Global Programme to Eliminate Lymphatic Filariasis is in
the effectiveness of combinations of different antifilarial drugs
(Ismail 1998; Shenoy 1999). Of particular interest is the effec-
tiveness of adding albendazole (thought to be macrofilaricidal)
(CDS/FIL 1998; Jayakody 1993) to single dose regimens of iver-
mectin (thought to be mainly microfilaricidal) or DEC (possibly
both microfilaricidal and macrofilaricidal) (Ottesen 1999).
All the included studies were designed primarily to assess the effec-
tiveness of albendazole for treatment of individuals, and none have
explicitly considered its effects on transmission in whole commu-
nities. We identified seven trials, but most of these were small. All
were described as randomized, but they had important limitations.
In particular, the numbers of participants lost to follow up were
very high (above 20%) in all trials except for Pani 2002, and this
may lead to imbalances in the comparison groups.
Differences in design (mf positive only versus positive and nega-
tive participants at baseline, variable outcome measurement and
reporting, and follow-up times) make it difficult to compare the
trials. In particular, some trials reported outcomes mainly for those
who were mf positive at baseline (Dunyo 2000; Kshirsagar 2004;
Simonsen 2004). Outcomes for all participants in the trial, regard-
less of baseline mf status, are essential in assessing the community
impact of mass treatment strategies. Most of the trials reported
changes in antigenaemia prevalence or density in addition to mf
prevalence and density (Dunyo 2000; Fox 2005; Kshirsagar 2004;
Pani 2002; Simonsen 2004). There was broad agreement between
changes in both these outcome measures in these trials. Only two
trials objectively examined the effects of antifilarial medication on
the viability of adult worms: Kshirsagar 2004 used a sample of the
enrolled participants (101 men at baseline) and Pani 2002 used 25
men at baseline. Adult worms are responsible for the production
of mf; therefore, the extent to which antifilarial drugs affect worm
viability is an important outcome.
Albendazole alone was not effective in reducing mf prevalence
(Beach 1999; Dunyo 2000; Fox 2005) or circulating filarial anti-
gens (Dunyo 2000; Fox 2005) compared with placebo. Ivermectin
was more effective than albendazole in both of these trials, and a
meta-analysis indicates a marginal but statistically significant 16%
reduction in the risk ratio of mf prevalence after treatment for
those who were mf positive at baseline in favour of ivermectin.
In two trials the combination of albendazole and ivermectin was
better than ivermectin alone in the short term (after four to six
months followup; Beach 1999; Simonsen 2004), but theywere the
same after twelve months of follow up (Dunyo 2000; Simonsen
2004). The lack of measurements at similar intervals in all three
trials makes it impossible to know if the results were substantially
alike. It is possible that by 12monthsmf levels had risen sufficiently
to dampen the actual effect of the drugs in Dunyo 2000, but this
cannot explain the lack of effect in Simonsen 2004. The dose of
ivermectin was also higher in the Haiti study (Beach 1999) than
the other two trials. The trials used different techniques to assess
mf: investigators in Haiti used the thick film method in 20 µL
of blood and measurement at night; in both Dunyo 2000 and
Simonsen 2004 the counting chamber method in 100 µL of blood
was used, with measurement during the day (Dunyo 2000) or at
night (Simonsen 2004).
Two very small trials in mf positive individuals and one larger pop-
ulation-based trial compared albendazole with DEC (Fox 2005;
Jayakody 1993; Pani 2002). The two small trials found no statis-
tically significant differences in mf prevalence or density at any of
the time points measured. Fox 2005 found a statistically signifi-
cant reduction in mf prevalence in favour of DEC at six months,
but no difference at three months.
Three trials also compared albendazole and DEC with both drugs
co-administered. The two small trials from India, Kshirsagar 2004
and Pani 2002, showed no statistically significant differences at
any time point up to two years follow up between DEC alone
and albendazole plus DEC. Fox 2005 found a reduction in mf
prevalence favouring the combination at six months, but this was
not statistically significant. There was no difference between the
combination and DEC alone at three months. None of the three
trials demonstrated any differences in antigen prevalence between
the combination and DEC alone. However, one of the three trials,
Fox 2005, did find a statistically significant reduction in geometric
mean mf density at six months in favour of the combination (al-
though there was no statistically significant difference in mf den-
sity at three months or antigen density at six months).
Although all trials provided data on geometric mean mf density,
a lack of reporting of standard deviations or confidence intervals
from most trials made it impossible to include these results in
a meta-analysis. A reduction in mf geometric mean density was
observed for all treatments including placebo, and the reduction
appeared greater for active treatments (albendazole, DEC, and
ivermectin), but tests of statistical significance were not always
carried out or reported.
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The effect of treatment on clinical disease was not remarkable in
any of the comparison groups. This is not surprising as effect sizes
for clinical outcomes were small and the trials were not powered
to detect small clinical benefits.
No serious adverse events were observed in six of the trials (Beach
1999; Dunyo 2000; Fox 2005; Kshirsagar 2004; Pani 2002;
Simonsen 2004). Jayakody 1993 found a very high incidence of
“scrotal syndrome” among those treated with albendazole, but the
doses of both albendazole and DEC were very much higher than
in the other trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on limited data, the evidence suggests that albendazole when
used alone is not better than placebo, ivermectin, or DEC in clear-
ing blood microfilariae. Results from trials that compared alben-
dazole plus ivermectin with ivermectin alone were inconsistent,
although two of three showed a reduction inmf density. Two small
trials found little difference in albendazole co-administered with
DEC compared with DEC alone, but one larger trial tended to
favour the combination at six months, with a significant reduction
in mf density. Most trials were underpowered to assess the effects
of albendazole, alone or in combination, on morbidity or adverse
events. Only larger scale studies can determine if any effect is of
practical importance.
The conclusions of this review are based on trials that have ran-
domized and treated individuals, therefore they should be cau-
tiously extrapolated to large-scale, population-based mass drug ad-
ministration programmes.
Implications for research
Only limited data were found − further large well-designed trials
are required in several areas including:
• the effectiveness of albendazole in combination with DEC
or ivermectin on treatment and control of lymphatic filariasis;
• the impact of albendazole in mass drug administration
campaigns; and
• studies of other interventions (against the parasite or the
vector) to augment mass drug administration.
The complete clearance of blood mf (or reduction to levels below
which transmission is unlikely) theoretically represents the most
reliable strategy for interrupting transmission. But this may be dif-
ficult to achieve in practice, as ivermectin mainly acts on mf with
no demonstrable macrofilaricidal activity. A drug that kills both
mf and adults would clearly be ideal, and there is an argument for
more research and development towards such a drug. Studies of
potential macrofilaricides could be assessed objectively, as with ul-
trasound detection, to directly monitor adult worms. It is also not
known how low microfilarial densities need to fall in order to suc-
cessfully interrupt transmission from the various vector species. As
microfilaraemia is an intermediate outcome reflecting infectivity
of the human host, it is important to assess comparative effective-
ness of drugs that aim to interrupt transmission. Techniques for
assessing mf in blood and outcome measures for mf densities need
to be standardized with complete reporting of geometric means
and standard deviations.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beach 1999
Methods Individually randomized controlled trial
Generation of allocation sequence: random-number table
Allocation concealment: concealed by third party
Blinding: “Double blind” stated, although drugs were not identical, patients had no way of identifying them; outcome
assessors blinded
Inclusion of all randomized participants in the analysis: 585 analysed of 965 randomized (61%)
Length of follow up: 4 months
Method of microfilariae (mf) assessment/volume of blood: thick smear; 20 µL of finger-prick blood
Participants Number randomized: 965, of whom 113 were mf positive
Children (male and female) aged 5 to 11 years with Wuchereria bancrofti filariasis
Interventions 1. Albendazole: 400 mg, 244 participants
2. Ivermectin: 200 to 400 µg/kg, 240 participants
3. Albendazole plus ivermectin: doses as above, 245 participants
4. Placebo: 229 participants
Outcomes 1. Post-treatment reduction in % mf prevalence
2. % reduction in geometric mean mf density (Note: standard deviation not reported; no values reported for the
albendazole group)
3. Prevalence of W. bancrofti among all children in each treatment group
4. Frequency of the occurrence of specific systemic adverse events, such as fever, headache, weakness, muscle/joint
pain, itching, rash, abdominal pain, and diarrhoea
Notes Location: Leogane, Haiti
Endemicity level: not stated
Dunyo 2000
Methods Individually randomized controlled trial
Generation of allocation sequence: computer generated
Allocation concealment: concealed by third party
Blinding: identical placebos used for each group
Inclusion of all randomized participants in the analysis: 273 analysed of 340 microfilariae (mf) positive randomized
(80%)
Length of follow up: 12 months
Method of mf assessment/volume of blood: mf in 100µL of finger-prick blood using the counting chamber technique,
daytime collection
Antigen testing: ELISA from finger-prick blood specimens
Participants Number randomized: 1425, of whom 340 mf positive were followed up
Individuals (male and female) aged 6 to 87 years with or without Wuchereria bancrofti
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Dunyo 2000 (Continued)
Interventions 1. Albendazole: 400 mg, 88 participants
2. Ivermectin: 150 to 200 µg/kg, 79 participants
3. Albendazole plus ivermectin: doses as above, 90 participants
4. Placebo: 83 participants
Outcomes 1. Number of individuals mf positive at 12 months post-treatment
2. Geometric mean mf density (Note: standard deviation not reported)
3. % of pretreatment mf concentration
4. Geometric mean circulating filarial antigen (CFA) density
5. Geometric mean CFA density as % of pretreatment value
6. New infections (appearance of antigenaemia)
7. New disease events (lymphoedema or hydrocoele)
8. Mortality during follow up
9. Frequency of specific systemic adverse events as well as the number of individuals presenting with any adverse
event post-treatment; reactions graded as 0 = none, 1 = mild (noticeable to patient but not interfering with daily
activities), 2 = moderate (some interference with daily activities), 3 = severe (complete interruption of daily activities)
(Note: Adjusted and unadjusted mf geometric mean mf intensities given)
Notes Location: southern Ghana (Butre, Achowa, Adjan, and Miamia villages)
Endemicity level: 18% to 25%
Fox 2005
Methods Individually randomized controlled trial
Generation of allocation sequence: random number table
Allocation concealment: unclear
Blinding: “Double blind” stated, although no dummy procedure; in reality, only outcome assessors likely to be ’blind’
Inclusion of all randomized participants in the analysis: 990 of 1292 (76%) analysed
Length of follow up: 6 months
Method of microfilariae (mf) assessment/volume of blood: 20 µL thick smear between 7:30 and 9:30 pm
Antigen testing: Og4C3 assay for circulating filarial antigen (CFA)
Participants Number randomized: 990
Children aged 5 to 11 years attending any of 12 selected primary schools
Interventions 1. Albendazole alone: 400 mg, 256 participants
2. Diethylcarbamazine (DEC) alone: 6 mg/kg body weight, 246 participants
3. Placebo: 243 participants
4. DEC and albendazole: doses as above, 245 participants
Outcomes 1. % of children in each group who had no mf detected in blood 3 and 6 months post-treatment
2. Mean % reduction in mf density 3 and 6 months post-treatment
3. Geometric mean % reduction in mf density 3 and 6 months post-treatment
4. CFA: % of children with negative CFA 6 months post-treatment
5. Mean % reduction in CFA density, geometric mean
6. % reduction in CFA density 6 months after treatment
7. Adverse events: assessed every day for 7 d after treatment by blinded clinicians who questioned and examined
children at school; adverse events recorded were self-reported or documented fever, headache, myalgias, and cough;
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Fox 2005 (Continued)
also reported a mean treatment impact score by day for the first seven days (1 = symptoms noticed, but did not
interfere with daily activities, 2 = symptoms caused some interference with daily activities, 3 = symptoms prevented
usual daily activities)
(Note: standard deviations for geometric mean density changes reported on request)
Notes Location: Leogane commune, Haiti
Endemicity level: 14.7% of children had mf and 31.4% were positive CFA at baseline
Jayakody 1993
Methods Individually randomized controlled trial
Generation of allocation sequence: pre-determined randomization list
Allocation concealment: states randomization list ’restricted’
Blinding: unclear
Inclusion of all randomized participants in the analysis: 20 analysed of 29 randomized (74%)
Length of follow up: 19 months
Method of microfilariae (mf) assessment/volume of blood: membrane filtration for using a Nucleopore filter (3 µm
pore size)
Participants Number randomized: 29
Asymptomatic men aged 18 to 65 with Wuchereria bancrofti mf
Patients with mf density in night blood films > 100 mf/mL at least once during previous week included
Interventions 1. Albendazole: 400 mg given twice daily for 21 d, 16 participants
2. Diethylcarbamazine (DEC): 6 mg/kg daily for 21 d, 13 participants
Outcomes 1. Post-treatment % prevalence reduction
2. % reduction in geometric mean mf density
3. Adverse events: the prevalence and severity of “scrotal syndrome” (pain in the scrotum, enlargement of epididymis,
and some systemic features, such as fever, thought to be caused by death of adult worms) during the treatment period
Notes Location: Colombo, Sri Lanka
Endemicity level: not stated
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Kshirsagar 2004
Methods Individually randomized controlled trial
Generation of allocation sequence: states randomized, exact details unclear
Allocation concealment: unclear
Blinding: used identical placebos and double dummy procedure
Inclusion of all randomized participants in the analysis: 1395/1403 (99%) analysed in safety study; 103 microfilariae
(mf)-positive men were selected for the efficacy study, but follow up of these was adequate at some time points but
inadequate at others
Length of follow up: 12 months
Method of mf assessment/volume of blood: thick smear, 60 µL of finger-prick blood or venepuncture between 9 and
11pm
Antigen testing: immunochromatographic card
Detection of adult filarial worm by USG machine; all regions of scrotum and spermatic cord systematically studied,
and “filaria dance sign” identified
Participants Number: 1403 randomized for safety study; 103 for efficacy assessment
Safety study: males and females over 5 years old with and without Wuchereria bancrofti
Efficacy assessment: males aged 18 to 50
Interventions 1. Diethylcarbamazine (DEC): 6 mg/kg body weight and albendazole 400 mg
2. DEC plus albendazole-placebo
Outcomes 1. Number mf positive at 3, 6, and 12 months (and % of pretreatment levels)
2. Number immunochromatographic card test (ICT) positive at 3, 6, and 12 months (and % pretreatment levels)
3. Number ultrasonography USG positive at 3, 6, and 12 months (and % pretreatment levels); results stratified
for those mf positive at baseline (43 participants), with clinical disease (30 participants), and mf negative and
asymptomatic (30 participants)
4. Adverse events: total incidence and number of participants with adverse drug reactions on days 2 or 5, number of
early terminations, number of participants where adverse events interfered with daily activities, and global assessment
of tolerability (very good or good, satisfactory, poor or insufficient, not assessable). Also categorized the severity of
adverse reactions according to the National Cancer Institute Common Toxicity Criteria (NCI 1999)
Notes Location: 2 endemic villages in Wardha, Maharashtra (Western India)
Endemicity level: 7.27% in 1995
Efficacy data: at many time points there were no men with clinical disease or mf negative at baseline surveyed
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Pani 2002
Methods Individually randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: adequate - coding of drugs performed by independent monitor
Blinding: comparable placebo and outcome assessors ’blind’
Inclusion of all randomized participants in the analysis: implies no losses to follow up (54 analysed out of 54
randomized)
Length of follow up: 24 months
Method of microfilariae (mf) assessment/volume of blood: not clear, 1 mL venous blood collected between 7:30 to
8:30 pm
Antigen testing: immunochromatographic card test and by Og4C3 ELISA test kit on 50 µL serum
Participants Number randomized: 54
Asymptomatic volunteers (male and female) between 10 and 57 years old who were mf positive
Interventions 1. Albendazole: 400 mg, 19 participants
2. Diethylcarbamazine (DEC): 6 mg/kg, 17 participants
3. Albendazole plus DEC: doses as above, 18 participants
Outcomes 1. % of individuals mf positive post-treatment
2. % reduction in geometric mean mf
3. % reduction in filarial antigen prevalence
4. Adverse events: monitored all participants in hospital for adverse reactions at 8-h intervals for the first 24 h, then
every 24 h for a further 3 d; proportion of individuals reporting any systemic adverse event and intensity (using a
simple scoring system) of adverse events were noted
(Note: no standard deviation reported for geometric mean mf density)
Notes Location: Pondicherry, India
Endemicity level: not given in report
Simonsen 2004
Methods Individually randomized controlled trial
Generation of allocation sequence: computer generated
Allocation concealment: concealed by third party
Blinding: used identical placebos and double dummy procedure
Inclusion of all randomized participants in the analysis: 1221 of 1829 (67%) analysed
Length of follow up: 12 months
Method of microfilariae (mf) assessment/volume of blood: 100 µL finger-prick blood, counting chamber technique
Antigen testing: circulating filarial antigen (CFA) on TropBio filter paper collection discs; blood sampling for mf and
CFA started at 9 pm
Participants Number randomized: 1829, of which 1221 (67%) followed up; 103 had mf
School children aged 6 to 18 years with or without Wuchereria bancrofti
Interventions 1. Albendazole plus ivermectin: 400 mg albendazole, 150 to 200 µg/kg ivermectin, 586 participants
2. Ivermectin alone: dose as above, 635 participants
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Simonsen 2004 (Continued)
Outcomes Results reported only in 103 mf-positive participants at baseline
1. Number of individuals mf positive at 6 and 12 months post-treatment
2. Geometric mean mf concentration and % of pretreatment geometric means at 6 and 12 months
3. Number of children CFA positive at 6 and 12 months and % of pretreatment CFA
4. Geometric mean density CFA and % of pretreatment CFA geometric mean density
5. New cases of mf positivity amongst those mf negative at baseline
6. New cases of CFA positivity amongst those CFA negative at baseline
7. Adverse reactions: children followed for 5 d after treatment by passive observation; specific adverse reactions,
such as headache, fever, joint pain, diarrhoea, dizziness, vomiting and itching noted, but number of events in each
treatment group not clearly reported
(Note: standard deviation not reported for geometric mean mf density)
Notes Location: 6 primary schools in coastal Tanzania
Endemicity level: known to be high; school mf prevalence was 17.3% overall for the 6 schools
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dunyo 2002 Update of Dunyo 2000 following retreatment of each treatment group; retreatment carried out only with the
combination (ALB plus IV), hence no comparison group given IV alone
Ismail 1998 The comparison groups - ALB versus ALB plus IV versus ALB plus DEC versus DEC plus IV - do not match
those in the review; these comparisons do not provide answers to the question as to whether adding ALB to IV
or DEC improves outcomes compared to IV or DEC alone; the comparisons would have to include IV alone or
DEC alone as comparators to be relevant to the review
Makunde 2003 Comparison groups do not match those in review; for single infections with Wuchereria bancrofti these were ALB
plus IV versus ALB alone; for co-infections of W. bancrofti and Onchocerca volvulus these were IV plus ALB versus
placebo
Shenoy 1999 The comparison groups - ALB versus ALB plus IV versus ALB plus DEC versus DEC plus IV - do not match those
in the review; excluded for reasons stated above for Ismail 1998
Shenoy 2002 Study of safety and tolerability of adding ALB to DEC; carried out only in patients without microfilariaemia (ie
presumably uninfected)
ALB: albendazole; DEC: diethylcarbamazine; IV: ivermectin.
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Characteristics of ongoing studies [ordered by study ID]
Dahoma (ongoing)
Trial name or title Assessment of safety and efficacy of ivermectin and albendazole co-administration
Methods -
Participants 1000 participants living in an area endemic for lymphatic filariasis and soil transmitted helminths in Zanzibar,
Tanzania
Interventions 1. Ivermectin
2. Albendazole plus ivermectin
Outcomes 1. Reappearance of microfilariae at 12 months
2. Microfilariae at 3 and 6 months
3. Adverse drug reactions
Starting date -
Contact information Mark Bradley
SmithKline Beecham
GlaxoWellcome House West
Berkeley Avenue
Greenford
Middlesex UB6 0NN
UK
Phone: +44 208 966 8543
Fax: +44 208 966 8827
Email: mhb38319@GlaxoWellcome.co.uk
Notes -
The names of principal investigator is used as the study ID.
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D A T A A N D A N A L Y S E S
Comparison 1. Albendazole versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microfilariae (mf) prevalence: all
participants (both mf positive
or negative at baseline)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 At 3 to 4 months 2 783 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.66, 1.37]
1.2 At 6 months 1 499 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.66, 1.53]
2 Microfilariae (mf) prevalence:
only participants mf positive at
baseline
2 195 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.87, 1.09]
3 Antigen prevalence: all
participants (both mf positive
or negative at baseline)
2 1090 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.81, 1.12]
4 New clinical disease 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Hydrocoele 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Pre-existing clinical disease 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Improvement in
lymphoedema
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 Improvement in
hydrocoele
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Systemic 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 2. Albendazole versus ivermectin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microfilariae (mf) prevalence: all
participants (both mf positive
or negative at baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Microfilariae (mf) prevalence:
only participants mf positive at
baseline
2 198 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.72, 0.98]
3 Antigen prevalence: all
participants (antigen positive
or negative at baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 New clinical disease 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Hydrocoele 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Pre-existing clinical disease 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Improvement in
lymphoedema
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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5.2 Improvement in
hydrocoele
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Systemic 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 3. Albendazole plus ivermectin versus ivermectin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microfilariae (mf) prevalence: all
participants (both mf positive
or negative at baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Microfilariae (mf) prevalence:
only participants mf positive at
baseline
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 At 4 to 6 months 2 255 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.18, 1.39]
2.2 At 12 months 2 348 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.13]
3 Antigen prevalence: all
participants (antigen positive
or negative) at baseline
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Antigen prevalence: only
participants antigen positive at
baseline
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Data at 6 months 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.2 Data at 12 months 2 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 New clinical disease 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Hydrocoele 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Pre-existing clinical disease 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Improvement in
lymphoedema
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.2 Improvement in
hydrocoele
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Adverse events 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Total 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.2 Systemic 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 4. Albendazole versus diethylcarbamazine (DEC)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microfiliariae (mf) prevalence:
all participants (both mf
positive or negative at baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 At 3 months 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 At 6 months 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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2 Microfilariae (mf) prevalence:
only participants mf positive at
baseline
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 After 3 months 1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.82, 1.10]
2.2 After 1 year 2 56 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.57, 2.49]
2.3 After 2 years 1 36 Risk Ratio (M-H, Fixed, 95% CI) 3.58 [0.44, 28.97]
3 Antigen prevalence: all
participants (both antigen
positive or negative at baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Antigen prevalence: only
participants antigen positive at
baseline
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 ICT test 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Adverse events: scrotal syndrome 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 5. Albendazole plus diethylcarbamazine (DEC) versus DEC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microfilariae (mf) prevalence: all
participants (both mf positive
or negative at baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 At 3 months 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 At 6 months 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Microfilariae (mf) prevalence:
only participants mf positive at
baseline
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 At 3 months 2 73 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.83, 1.36]
2.2 At 6 months 1 42 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.62, 1.61]
2.3 At 12 months 2 78 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.69, 1.44]
2.4 At 2 years 1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.06, 13.93]
3 Antigen prevalence: all
participants (both antigen
positive and negative at
baseline)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Data at 6 months 2 592 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.82, 1.24]
3.2 Data at 12 months 1 103 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.69, 1.31]
4 Antigen prevalence: only
participants antigen positive at
baseline
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Adverse events 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Any 2 1430 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.71, 1.08]
5.2 Interfered with daily
activities
1 1395 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.64, 1.73]
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Analysis 1.1. Comparison 1 Albendazole versus placebo, Outcome 1 Microfilariae (mf) prevalence: all
participants (both mf positive or negative at baseline).
Review: Albendazole for lymphatic filariasis
Comparison: 1 Albendazole versus placebo
Outcome: 1 Microfilariae (mf) prevalence: all participants (both mf positive or negative at baseline)
Study or subgroup Albendazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 3 to 4 months
Beach 1999 22/145 20/139 39.9 % 1.05 [ 0.60, 1.84 ]
Fox 2005 28/256 30/243 60.1 % 0.89 [ 0.55, 1.44 ]
Subtotal (95% CI) 401 382 100.0 % 0.95 [ 0.66, 1.37 ]
Total events: 50 (Albendazole), 50 (Placebo)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
2 At 6 months
Fox 2005 38/256 36/243 100.0 % 1.00 [ 0.66, 1.53 ]
Subtotal (95% CI) 256 243 100.0 % 1.00 [ 0.66, 1.53 ]
Total events: 38 (Albendazole), 36 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
0.2 0.5 1 2 5
Favours albendazole Favours placebo
27Albendazole for lymphatic filariasis (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Albendazole versus placebo, Outcome 2 Microfilariae (mf) prevalence: only
participants mf positive at baseline.
Review: Albendazole for lymphatic filariasis
Comparison: 1 Albendazole versus placebo
Outcome: 2 Microfilariae (mf) prevalence: only participants mf positive at baseline
Study or subgroup Albendazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Beach 1999 22/29 20/29 23.7 % 1.10 [ 0.80, 1.51 ]
Dunyo 2000 62/71 62/66 76.3 % 0.93 [ 0.83, 1.04 ]
Total (95% CI) 100 95 100.0 % 0.97 [ 0.87, 1.09 ]
Total events: 84 (Albendazole), 82 (Placebo)
Heterogeneity: Chi2 = 1.20, df = 1 (P = 0.27); I2 =16%
Test for overall effect: Z = 0.52 (P = 0.60)
0.5 0.7 1 1.5 2
Favours albendazole Favours placebo
Analysis 1.3. Comparison 1 Albendazole versus placebo, Outcome 3 Antigen prevalence: all participants
(both mf positive or negative at baseline).
Review: Albendazole for lymphatic filariasis
Comparison: 1 Albendazole versus placebo
Outcome: 3 Antigen prevalence: all participants (both mf positive or negative at baseline)
Study or subgroup Albendazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dunyo 2000 115/302 102/289 51.9 % 1.08 [ 0.87, 1.33 ]
Fox 2005 81/256 94/243 48.1 % 0.82 [ 0.64, 1.04 ]
Total (95% CI) 558 532 100.0 % 0.95 [ 0.81, 1.12 ]
Total events: 196 (Albendazole), 196 (Placebo)
Heterogeneity: Chi2 = 2.87, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.59 (P = 0.56)
0.5 0.7 1 1.5 2
Favours albendazole Favours placebo
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Analysis 1.4. Comparison 1 Albendazole versus placebo, Outcome 4 New clinical disease.
Review: Albendazole for lymphatic filariasis
Comparison: 1 Albendazole versus placebo
Outcome: 4 New clinical disease
Study or subgroup Albendazole Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hydrocoele
Dunyo 2000 1/129 1/126 0.98 [ 0.06, 15.45 ]
0.01 0.1 1 10 100
Favours albendazole Favours placebo
Analysis 1.5. Comparison 1 Albendazole versus placebo, Outcome 5 Pre-existing clinical disease.
Review: Albendazole for lymphatic filariasis
Comparison: 1 Albendazole versus placebo
Outcome: 5 Pre-existing clinical disease
Study or subgroup Albendazole Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Improvement in lymphoedema
Dunyo 2000 3/13 2/9 1.04 [ 0.22, 5.01 ]
2 Improvement in hydrocoele
Dunyo 2000 3/8 5/10 0.75 [ 0.25, 2.23 ]
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours albendazole
29Albendazole for lymphatic filariasis (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Albendazole versus placebo, Outcome 6 Adverse events.
Review: Albendazole for lymphatic filariasis
Comparison: 1 Albendazole versus placebo
Outcome: 6 Adverse events
Study or subgroup Albendazole Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic
Dunyo 2000 31/336 33/314 0.88 [ 0.55, 1.40 ]
0.2 0.5 1 2 5
Favours albendazole Favours placebo
Analysis 2.1. Comparison 2 Albendazole versus ivermectin, Outcome 1 Microfilariae (mf) prevalence: all
participants (both mf positive or negative at baseline).
Review: Albendazole for lymphatic filariasis
Comparison: 2 Albendazole versus ivermectin
Outcome: 1 Microfilariae (mf) prevalence: all participants (both mf positive or negative at baseline)
Study or subgroup Albendazole Ivermectin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Beach 1999 22/145 20/150 1.14 [ 0.65, 1.99 ]
0.1 0.2 0.5 1 2 5 10
Favours albendazole Favours ivermectin
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Analysis 2.2. Comparison 2 Albendazole versus ivermectin, Outcome 2 Microfilariae (mf) prevalence: only
participants mf positive at baseline.
Review: Albendazole for lymphatic filariasis
Comparison: 2 Albendazole versus ivermectin
Outcome: 2 Microfilariae (mf) prevalence: only participants mf positive at baseline
Study or subgroup Ivermectin Albendazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Beach 1999 17/28 22/29 26.0 % 0.80 [ 0.56, 1.15 ]
Dunyo 2000 52/70 62/71 74.0 % 0.85 [ 0.72, 1.00 ]
Total (95% CI) 98 100 100.0 % 0.84 [ 0.72, 0.98 ]
Total events: 69 (Ivermectin), 84 (Albendazole)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
0.5 0.7 1 1.5 2
Favours ivermectin Favours albendazole
Analysis 2.3. Comparison 2 Albendazole versus ivermectin, Outcome 3 Antigen prevalence: all participants
(antigen positive or negative at baseline).
Review: Albendazole for lymphatic filariasis
Comparison: 2 Albendazole versus ivermectin
Outcome: 3 Antigen prevalence: all participants (antigen positive or negative at baseline)
Study or subgroup Albendazole Ivermectin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dunyo 2000 115/302 101/283 1.07 [ 0.86, 1.32 ]
0.5 0.7 1 1.5 2
Favours albendazole Favours ivermectin
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Analysis 2.4. Comparison 2 Albendazole versus ivermectin, Outcome 4 New clinical disease.
Review: Albendazole for lymphatic filariasis
Comparison: 2 Albendazole versus ivermectin
Outcome: 4 New clinical disease
Study or subgroup Albendazole Ivermectin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hydrocoele
Dunyo 2000 1/129 1/133 1.03 [ 0.07, 16.31 ]
0.01 0.1 1 10 100
Favours albendazole Favours ivermectin
Analysis 2.5. Comparison 2 Albendazole versus ivermectin, Outcome 5 Pre-existing clinical disease.
Review: Albendazole for lymphatic filariasis
Comparison: 2 Albendazole versus ivermectin
Outcome: 5 Pre-existing clinical disease
Study or subgroup Albendazole Ivermectin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Improvement in lymphoedema
Dunyo 2000 3/13 2/13 1.50 [ 0.30, 7.55 ]
2 Improvement in hydrocoele
Dunyo 2000 3/8 2/9 1.69 [ 0.37, 7.67 ]
0.1 0.2 0.5 1 2 5 10
Favours ivermectin Favours albendazole
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Analysis 2.6. Comparison 2 Albendazole versus ivermectin, Outcome 6 Adverse events.
Review: Albendazole for lymphatic filariasis
Comparison: 2 Albendazole versus ivermectin
Outcome: 6 Adverse events
Study or subgroup Albendazole Ivermectin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic
Dunyo 2000 31/336 36/295 0.76 [ 0.48, 1.19 ]
0.2 0.5 1 2 5
Favours albendazole Favours ivermectin
Analysis 3.1. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 1 Microfilariae (mf)
prevalence: all participants (both mf positive or negative at baseline).
Review: Albendazole for lymphatic filariasis
Comparison: 3 Albendazole plus ivermectin versus ivermectin
Outcome: 1 Microfilariae (mf) prevalence: all participants (both mf positive or negative at baseline)
Study or subgroup ALB plus IV Ivermectin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Beach 1999 7/151 20/150 0.35 [ 0.15, 0.80 ]
0.1 0.2 0.5 1 2 5 10
Favours ALB plus IV Favours ivermectin
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Analysis 3.2. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 2 Microfilariae (mf)
prevalence: only participants mf positive at baseline.
Review: Albendazole for lymphatic filariasis
Comparison: 3 Albendazole plus ivermectin versus ivermectin
Outcome: 2 Microfilariae (mf) prevalence: only participants mf positive at baseline
Study or subgroup ALB plus IV Ivermectin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 At 4 to 6 months
Beach 1999 4/24 17/28 16.0 % 0.27 [ 0.11, 0.70 ]
Simonsen 2004 67/105 85/98 84.0 % 0.74 [ 0.62, 0.87 ]
Subtotal (95% CI) 129 126 100.0 % 0.49 [ 0.18, 1.39 ]
Total events: 71 (ALB plus IV), 102 (Ivermectin)
Heterogeneity: Tau2 = 0.46; Chi2 = 4.82, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 1.34 (P = 0.18)
2 At 12 months
Dunyo 2000 58/75 52/70 49.3 % 1.04 [ 0.87, 1.25 ]
Simonsen 2004 75/105 73/98 50.7 % 0.96 [ 0.81, 1.13 ]
Subtotal (95% CI) 180 168 100.0 % 1.00 [ 0.88, 1.13 ]
Total events: 133 (ALB plus IV), 125 (Ivermectin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
0.1 0.2 0.5 1 2 5 10
Favours ALB plus IV Favours ivermectin
Analysis 3.3. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 3 Antigen prevalence:
all participants (antigen positive or negative) at baseline.
Review: Albendazole for lymphatic filariasis
Comparison: 3 Albendazole plus ivermectin versus ivermectin
Outcome: 3 Antigen prevalence: all participants (antigen positive or negative) at baseline
Study or subgroup ALB plus IV Ivermectin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dunyo 2000 122/307 101/283 1.11 [ 0.90, 1.37 ]
0.5 0.7 1 1.5 2
Favours ALB plus IV Favours ivermectin
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Analysis 3.4. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 4 Antigen prevalence:
only participants antigen positive at baseline.
Review: Albendazole for lymphatic filariasis
Comparison: 3 Albendazole plus ivermectin versus ivermectin
Outcome: 4 Antigen prevalence: only participants antigen positive at baseline
Study or subgroup ALB plus IV Ivermectin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Data at 6 months
Simonsen 2004 227/247 242/266 1.01 [ 0.96, 1.07 ]
2 Data at 12 months
Dunyo 2000 111/121 89/99 1.02 [ 0.94, 1.11 ]
Simonsen 2004 227/247 236/266 1.04 [ 0.98, 1.10 ]
0.5 0.7 1 1.5 2
Favours ALB plus IV Favours ivermectin
Analysis 3.5. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 5 New clinical disease.
Review: Albendazole for lymphatic filariasis
Comparison: 3 Albendazole plus ivermectin versus ivermectin
Outcome: 5 New clinical disease
Study or subgroup ALB plus IV Ivermectin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hydrocoele
Dunyo 2000 2/147 1/133 1.81 [ 0.17, 19.73 ]
0.01 0.1 1 10 100
Favours ALB plus IV Favours ivermectin
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Analysis 3.6. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 6 Pre-existing clinical
disease.
Review: Albendazole for lymphatic filariasis
Comparison: 3 Albendazole plus ivermectin versus ivermectin
Outcome: 6 Pre-existing clinical disease
Study or subgroup ALB plus IV Ivermectin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Improvement in lymphoedema
Dunyo 2000 2/13 2/13 1.00 [ 0.16, 6.07 ]
2 Improvement in hydrocoele
Dunyo 2000 4/10 2/9 1.80 [ 0.43, 7.59 ]
0.1 0.2 0.5 1 2 5 10
Favours ivermectin Favours ALB plus IV
Analysis 3.7. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 7 Adverse events.
Review: Albendazole for lymphatic filariasis
Comparison: 3 Albendazole plus ivermectin versus ivermectin
Outcome: 7 Adverse events
Study or subgroup ALB plus ivermectin IV Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Total
Simonsen 2004 0/1 0/1 0.0 [ 0.0, 0.0 ]
2 Systemic
Dunyo 2000 47/332 36/295 1.16 [ 0.77, 1.74 ]
0.2 0.5 1 2 5
Favours ALB plus IV Favours ivermectin
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Analysis 4.1. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 1 Microfiliariae (mf)
prevalence: all participants (both mf positive or negative at baseline).
Review: Albendazole for lymphatic filariasis
Comparison: 4 Albendazole versus diethylcarbamazine (DEC)
Outcome: 1 Microfiliariae (mf) prevalence: all participants (both mf positive or negative at baseline)
Study or subgroup Albendazole DEC Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 3 months
Fox 2005 28/256 24/246 1.12 [ 0.67, 1.88 ]
2 At 6 months
Fox 2005 38/256 21/246 1.74 [ 1.05, 2.88 ]
0.1 0.2 0.5 1 2 5 10
Favours albendazole Favours DEC
Analysis 4.2. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 2 Microfilariae (mf)
prevalence: only participants mf positive at baseline.
Review: Albendazole for lymphatic filariasis
Comparison: 4 Albendazole versus diethylcarbamazine (DEC)
Outcome: 2 Microfilariae (mf) prevalence: only participants mf positive at baseline
Study or subgroup Albendazole DEC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 After 3 months
Pani 2002 18/19 17/17 100.0 % 0.95 [ 0.82, 1.10 ]
Subtotal (95% CI) 19 17 100.0 % 0.95 [ 0.82, 1.10 ]
Total events: 18 (Albendazole), 17 (DEC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 After 1 year
Jayakody 1993 5/10 5/10 61.2 % 1.00 [ 0.42, 2.40 ]
Pani 2002 5/19 3/17 38.8 % 1.49 [ 0.42, 5.33 ]
Subtotal (95% CI) 29 27 100.0 % 1.19 [ 0.57, 2.49 ]
0.01 0.1 1 10 100
Favours albendazole Favours DEC
(Continued . . . )
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(. . . Continued)
Study or subgroup Albendazole DEC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 10 (Albendazole), 8 (DEC)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
3 After 2 years
Pani 2002 4/19 1/17 100.0 % 3.58 [ 0.44, 28.97 ]
Subtotal (95% CI) 19 17 100.0 % 3.58 [ 0.44, 28.97 ]
Total events: 4 (Albendazole), 1 (DEC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
0.01 0.1 1 10 100
Favours albendazole Favours DEC
Analysis 4.3. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 3 Antigen prevalence:
all participants (both antigen positive or negative at baseline).
Review: Albendazole for lymphatic filariasis
Comparison: 4 Albendazole versus diethylcarbamazine (DEC)
Outcome: 3 Antigen prevalence: all participants (both antigen positive or negative at baseline)
Study or subgroup Albendazole DEC Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fox 2005 94/256 73/246 1.24 [ 0.96, 1.59 ]
0.5 0.7 1 1.5 2
Favours albendazole Favours DEC
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Analysis 4.4. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 4 Antigen prevalence:
only participants antigen positive at baseline.
Review: Albendazole for lymphatic filariasis
Comparison: 4 Albendazole versus diethylcarbamazine (DEC)
Outcome: 4 Antigen prevalence: only participants antigen positive at baseline
Study or subgroup Albendazole DEC Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ICT test
Pani 2002 6/19 2/17 2.68 [ 0.62, 11.56 ]
0.001 0.01 0.1 1 10 100 1000
Favours albendazole Favours DEC
Analysis 4.5. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 5 Adverse events.
Review: Albendazole for lymphatic filariasis
Comparison: 4 Albendazole versus diethylcarbamazine (DEC)
Outcome: 5 Adverse events
Study or subgroup Albendazole DEC Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pani 2002 8/19 9/17 0.80 [ 0.40, 1.59 ]
0.1 0.2 0.5 1 2 5 10
Favours albendazole Favours DEC
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Analysis 4.6. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 6 Adverse events:
scrotal syndrome.
Review: Albendazole for lymphatic filariasis
Comparison: 4 Albendazole versus diethylcarbamazine (DEC)
Outcome: 6 Adverse events: scrotal syndrome
Study or subgroup Albendazole DEC Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jayakody 1993 7/15 0/12 12.19 [ 0.77, 194.03 ]
0.001 0.01 0.1 1 10 100 1000
Favours albendazole Favours DEC
Analysis 5.1. Comparison 5 Albendazole plus diethylcarbamazine (DEC) versus DEC, Outcome 1
Microfilariae (mf) prevalence: all participants (both mf positive or negative at baseline).
Review: Albendazole for lymphatic filariasis
Comparison: 5 Albendazole plus diethylcarbamazine (DEC) versus DEC
Outcome: 1 Microfilariae (mf) prevalence: all participants (both mf positive or negative at baseline)
Study or subgroup ALB plus DEC DEC Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 3 months
Fox 2005 23/245 24/246 0.96 [ 0.56, 1.66 ]
2 At 6 months
Fox 2005 13/245 21/246 0.62 [ 0.32, 1.21 ]
0.1 0.2 0.5 1 2 5 10
Favours ALB plus DEC Favours DEC
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Analysis 5.2. Comparison 5 Albendazole plus diethylcarbamazine (DEC) versus DEC, Outcome 2
Microfilariae (mf) prevalence: only participants mf positive at baseline.
Review: Albendazole for lymphatic filariasis
Comparison: 5 Albendazole plus diethylcarbamazine (DEC) versus DEC
Outcome: 2 Microfilariae (mf) prevalence: only participants mf positive at baseline
Study or subgroup ALB plus DEC DEC Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 3 months
Kshirsagar 2004 17/19 16/19 1.06 [ 0.83, 1.36 ]
Pani 2002 18/18 17/17 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 37 36 1.06 [ 0.83, 1.36 ]
Total events: 35 (ALB plus DEC), 33 (DEC)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
2 At 6 months
Kshirsagar 2004 13/21 13/21 1.00 [ 0.62, 1.61 ]
Subtotal (95% CI) 21 21 1.00 [ 0.62, 1.61 ]
Total events: 13 (ALB plus DEC), 13 (DEC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 At 12 months
Kshirsagar 2004 9/22 7/21 1.23 [ 0.56, 2.69 ]
Pani 2002 13/18 14/17 0.88 [ 0.61, 1.26 ]
Subtotal (95% CI) 40 38 0.99 [ 0.69, 1.44 ]
Total events: 22 (ALB plus DEC), 21 (DEC)
Heterogeneity: Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
4 At 2 years
Pani 2002 1/18 1/17 0.94 [ 0.06, 13.93 ]
Subtotal (95% CI) 18 17 0.94 [ 0.06, 13.93 ]
Total events: 1 (ALB plus DEC), 1 (DEC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
0.01 0.1 1 10 100
Favours ALB plus DEC Favours DEC
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Analysis 5.3. Comparison 5 Albendazole plus diethylcarbamazine (DEC) versus DEC, Outcome 3 Antigen
prevalence: all participants (both antigen positive and negative at baseline).
Review: Albendazole for lymphatic filariasis
Comparison: 5 Albendazole plus diethylcarbamazine (DEC) versus DEC
Outcome: 3 Antigen prevalence: all participants (both antigen positive and negative at baseline)
Study or subgroup ALB plus DEC DEC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Data at 6 months
Fox 2005 75/245 73/246 68.9 % 1.03 [ 0.79, 1.35 ]
Kshirsagar 2004 32/52 32/49 31.1 % 0.94 [ 0.70, 1.27 ]
Subtotal (95% CI) 297 295 100.0 % 1.00 [ 0.82, 1.24 ]
Total events: 107 (ALB plus DEC), 105 (DEC)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Data at 12 months
Kshirsagar 2004 30/52 31/51 100.0 % 0.95 [ 0.69, 1.31 ]
Subtotal (95% CI) 52 51 100.0 % 0.95 [ 0.69, 1.31 ]
Total events: 30 (ALB plus DEC), 31 (DEC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
0.1 0.2 0.5 1 2 5 10
Favours ALB plus DEC Favours DEC
Analysis 5.4. Comparison 5 Albendazole plus diethylcarbamazine (DEC) versus DEC, Outcome 4 Antigen
prevalence: only participants antigen positive at baseline.
Review: Albendazole for lymphatic filariasis
Comparison: 5 Albendazole plus diethylcarbamazine (DEC) versus DEC
Outcome: 4 Antigen prevalence: only participants antigen positive at baseline
Study or subgroup ALB plus DEC DEC Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pani 2002 5/18 2/17 2.36 [ 0.53, 10.58 ]
0.01 0.1 1 10 100
Favours ALB plus DEC Favours DEC
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Analysis 5.5. Comparison 5 Albendazole plus diethylcarbamazine (DEC) versus DEC, Outcome 5 Adverse
events.
Review: Albendazole for lymphatic filariasis
Comparison: 5 Albendazole plus diethylcarbamazine (DEC) versus DEC
Outcome: 5 Adverse events
Study or subgroup ALB plus DEC DEC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any
Kshirsagar 2004 120/702 138/693 93.8 % 0.86 [ 0.69, 1.07 ]
Pani 2002 11/18 9/17 6.2 % 1.15 [ 0.65, 2.06 ]
Subtotal (95% CI) 720 710 100.0 % 0.88 [ 0.71, 1.08 ]
Total events: 131 (ALB plus DEC), 147 (DEC)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
2 Interfered with daily activities
Kshirsagar 2004 31/702 29/693 100.0 % 1.06 [ 0.64, 1.73 ]
Subtotal (95% CI) 702 693 100.0 % 1.06 [ 0.64, 1.73 ]
Total events: 31 (ALB plus DEC), 29 (DEC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
0.2 0.5 1 2 5
Favours ALB plus DEC Favours DEC
A P P E N D I C E S
Appendix 1. Search methods: detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 filaria* filaria* FILARIASIS FILARIASIS filaria*
2 albendazole elephantiasis lymphatic filariasis lymphatic filariasis elephantiasis
3 benzimidazole lymphedema ELEPHANTIASIS ELEPHANTIASIS lymphedema
4 - wuchereria LYMPHEDEMA lymphedema wuchereria
5 - brugia Wuchereria bancrofti Wuchereria bancrofti brugia
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(Continued)
6 - 1 or 2 or 3 or 4 or 5 BRUGIA BRUGIA 1 or 2 or 3 or 4 or 5
7 - diethylcarbamazine 1 or 2 or 3 or 4 or 5 or 6 1 or 2 or 3 or 4 or 5 or 6 diethylcarbamazine
8 - ivermectin FILARICIDES diethylcarbamazine ivermectin
9 - benzimidazole diethylcarbamazine ivermectin benzimidazole
10 - albendazole ivermectin benzimidazole albendazole
11 - carbamazine benzimidazole albendazole carbamazine
12 - hetrazan albendazole carbamazine hetrazan
13 - luxuran carbamazine hetrazan luxuran
14 - mectizan hetrazan luxuran mectizan
15 - metiazol luxuran mectizan metiazol
16 - valbazen mectizan metiazol valbazen
17 - 7-16/OR metiazol valbazen 7-16/OR
18 - 6 and 17 valbazen 8-17/OR 6 and 17
19 - Limit 18 to human 8-18/OR 7 and 18 -
20 - - 7 and 19 Limit 19 to human -
21 - - Limit 20 to human - -
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Higgins
2005); Upper case: MeSH or EMTREE heading; Lower case: free text term.
Appendix 2. Risk of bias assessmenta
Trial Allocation sequence gen-
eration
Allocation concealment Blinding Inclusiona
Beach 1999 Adequate Adequate Reported as “double blind” Inadequate
Dunyo 2000 Adequate Adequate Double blind Inadequate
Fox 2005 Adequate Unclear Outcome assessors Inadequate
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(Continued)
Jayakody 1993 Unclear Unclear Unclear Inadequate
Kshirsagar 2004 Unclear Unclear Double blind Adequate (safety study)
Adequate or inadequate
depending on time point
(efficacy study)
Pani 2002 Unclear Adequate Double blind Adequate
Simonsen 2004 Adequate Adequate Double blind Inadequate
aSee the ’Assessment of risk of bias in included studies’ for the assessment methods, and the ’Characteristics of included studies’ for
the methods used in each trial.
bInclusion of all randomized participants in the final analysis.
Appendix 3. Microfilariae prevalence
Comparison Trial Intervention No. participants +ve post-treat-
ment
% baseline [re-
ductn]
Note
ALB vs placebo Dunyo 2000 ALB 71 62 87.3 -
Placebo 66 62 93.9 -
Beach 1999 ALB 29 4 months: 22 75.9 Only partici-
pants mf positive
at baseline
Placebo 29 4 months: 20 69.0 -
Beach 1999 ALB 145 4 months: 22 [15.4] Values for partic-
ipants regardless
of mf status at
baseline
26 (17.9%) mf-
positive at base-
line
Placebo 139 4 months: 20 [20.0] 25 (18.0%) mf-
positive at base-
line
Fox 2005 ALB 256 3 months: 28
6 months: 38
- -
Placebo 243 3 months: 30
6 months: 36
- -
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(Continued)
ALB vs IV Dunyo 2000 ALB 71 6 months: 62 87.3 -
IV 70 6 months: 52 74.3 -
Beach 1999 ALB 145 4 months: 22 [15.4] Values for partic-
ipants regardless
of mf status at
baseline
26 (17.9%) mf-
positive at base-
line
IV 140 4 months: 20 [23.1] 26 (17.3%) mf-
positive at base-
line
Beach 1999 ALB 29 4 months: 22 75.9 Only partici-
pants mf positive
at baseline
IV 28 4 months: 17 60.7 -
ALB plus IV vs
IV
Dunyo 2000 ALB plus IV 75 6 months: 58 77.3 -
IV 70 6 months: 52 74.3 -
Beach 1999 ALB plus IV 24 4 months: 4 16.7 Only partici-
pants mf positive
at baseline
IV 28 4 months: 17 60.7 -
Simonsen 2004 ALB plus IV 105 6 months: 67
12 months: 75
6 months: 63.8
12 months: 71.4
-
IV 98 6 months: 85
12 months: 73
6 months: 86.7
12 months: 74.5
-
ALB vs DEC Pani 2002 ALB 19 30 d: 0
90 d: 18
360 d: 14
2 yr: 4
- -
DEC 17 30 d: 0
90 d: 17
360 d: 14
2 yr: 1
- -
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(Continued)
Jayakody 1993 ALB 16 28 d: 12/15
3
months: denom-
inator unclear
6 months: num-
bers unclear
5 to 19 months:
5/10
- -
DEC 13 28 d: 7/12
3 months: 9/12
6 months: 8/12
15 to 19 months:
5/10
- -
Fox 2005 ALB 256 3 months: 28
6 months: 38
- -
DEC 246 3 months: 24
6 months: 21
- -
ALB plus DEC
vs DEC
Pani 2002 ALB plus DEC 18 30 d: 0
90 d: 18
360 d: 14
2 yr: 1
- -
DEC 17 30 d: 0
90 d: 17
360 d: 14
2 yr: 1
- -
Fox 2005 ALB plus DEC 245 3 months: 23
6 months: 13
- -
DEC 246 3 months: 24
6 months: 21
- -
Kshirsagar 2004 ALB plus DEC Varies 3months: 17/19
6months: 13/21
12 months: 13/
18
- -
DEC Varies 3months: 16/19
6months: 13/21
12 months: 14/
17
- -
ALB: albendazole; DEC: diethylcarbamazine; IV: ivermectin; mf: microfilariae.
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Appendix 4. Antigen prevalence
Comparison Trial Outcome
measure
Intervention No.
participants
% reduction Pretreatment Post-
treatment
ALB vs
placebo
Dunyo 2000 CFA positive ALB - - 105 110
Placebo - - 103 102
Fox 2005 CFA positivea ALB 256 - 89 (34.8) 94 (36.7%)
Placebo 243 - 74 (30.5%) 81 (33.3%)
ALB vs IV Dunyo 2000 CFA positive ALB - - 105 110
IV - - 99 101
ALB plus IV
vs IV
Dunyo 2000 CFA positive ALB plus IV - - 121 122
IV - - 99 101
Simonsen
2004
CFA positive* ALB plus IV 247 6 months:
91.9%
12 months:
91.9%
247 6 months:
226
12 months:
227
IV 266 6 months:
91.0%
12 months:
88.7%
266 6 months:
242
12 months:
236
ALB vs DEC Pani 2002 Antigen posi-
tivityb
ALB 19 360 d: 83 - -
DEC 17 360 d: 87 - -
Pani 2002 Antigen posi-
tivityc
ALB 19 360 d: 83 - -
DEC 17 360 d: 80 - -
Fox 2005 CFA positivea ALB 256 - 89 (34.8) 94 (36.7%)
DEC 246 - 79 (32.1%) 73 (29.7%)
ALB plus
DEC vs DEC
Pani 2002 Antigen posi-
tivityb
ALB plus
DEC
18 360 d: 75 - -
DEC 17 360 d: 87 - -
Pani 2002 Antigen posi-
tivityc
ALB plus
DEC
18 360 d: 81 - -
DEC 17 360 d: 80 - -
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(Continued)
Fox 2005 CFA positivea ALB plus
DEC
245 - 85 (34.7%) 75 (30.6%)
DEC 246 - 79 (32.1%) 73 (29.7%)
ALB: albendazole; CFA: circulating filarial antigen; DEC: diethylcarbamazine; IV: ivermectin.
aAmong children CFA positive at baseline.
bImmunochromatographic card test on 50 µL serum.
cOg4C3 test kit on 50 µL serum.
Appendix 5. Microfilariae density (geometric mean)
Comparison Trial Measure Intervention No.
participants
Pretreatment Post-
treatment
% reduction
ALB vs
placebo
Dunyo 2000 mf/100 µL ALB 71 798 12 months:
251
68.5
Placebo 66 971 12 months:
845
13.0
Dunyo 2000 mf/
100 µL mea-
sured by AUC
a
ALB 42 1535 12 months:
1233
19.7
Placebo 32 2536 12 months:
2740
108.4 (8.4%
increase)
Beach 1999b mf/20 µL ALB 28 14.1 4 months: 5.1 28.7 (63.8c)
Placebo 29 9.3 4 months: 5.3 17.2 (43.0c)
Fox 2005 mf/20 µL ALB 256 12.1 (95% CI
10.3 to 14.2)
3 months: 4.7
(95% CI 3.9
to 5.7)
6 months: 4.4
(95% CI 3.7
to 5.3)
3 months:
22.0
6 months:
34.7
Placebo 243 17.3 (95% CI
14.5 to 20.6)
3 months: 8.7
(95% CI 7.4
to 10.2)
6 months:
11.2 (95% CI
9.2 to 13.7)
3 months: 8.2
6 months:
10.3
ALB vs IV Dunyo 2000 mf/100 µL ALB 71 798 12 months:
251
68.5
IV 70 640 12 months:
124
80.6
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(Continued)
Dunyo 2000 mf/
100 µL mea-
sured by AUC
a
ALB 42 1535 12 months:
1233
19.7
IV 33 1731 12 months:
759
43.8
Beach 1999 mf/20 µL ALB 28 14.1 4 months: 5.1 28.7 (63.8c)
IV 28 15.5 4 months: 1.5 76.1 (90.2c)
ALB plus IV
vs IV
Dunyo 2000 mf/100 µL ALB plus IV 75 614 12 months: 78 87.3IV 0 40 months:
124
0 6
Dunyo 2000 mf/
100 µL mea-
sured by AUC
a
ALB plus IV 40 1280 12 months:
393
30.7
IV 33 1731 12 months:
759
56.2
Beach 1999b mf/20 µL ALB plus IV 24 13.7 4 months: 0.3 98.9 (97.8c)
IV 28 15.5 4 months: 1.5 76.1 (90.2c)
Simonsen
2004
mf/100 µL ALB plus IV 105 812.6 6 months:
29.8
12 months:
59.4
6 months:
96.3
12 months:
83.6
IV 98 763.5 6 months:
150.0 12
months:
124.9
6 months:
80.4
12 months:
83.6
ALB vs DEC Pani 2002 mf/mL ALB 19 77.6 (range 22
to 606)
- 3 d: 8.7
7 d: 14.1
360 d: 94.7
DEC 17 81.3 (range 22
to 542)
- 3 d: 26.2
7 d: 36.7
360 d: 89.6
Jayakody
1993
mf/mL ALB 16 633 +/- 150 15 to 19
months: 3
6 months:
1.91
DEC 13 566 +/- 120 15 to 19
months: 2
6 months:
0.81
Fox 2005 mf/20 µL ALB 256 12.1 (95% CI
10.3 to 14.2)
3 months: 4.7
(95% CI 3.9
to 5.7)
3 months:
22.0
6 months:
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(Continued)
6 months: 4.4
(95% CI 3.7
to 5.3)
34.7
DEC 246 12.9 (95% CI
11.0 to 15.2)
3 months: 2.9
(95% CI 2.5
to 3.4)
6 months: 2.8
(95% CI 2.3
to 3.4)
3 months:
31.3
6 months:
50.4
ALB plus
DEC vs DEC
Pani 2002 mf/mL ALB plus
DEC
18 79.4 (range 22
to 233)
- 3 d: 35.7
7 d: 45.1
360 d: 95.4
DEC 17 81.3 (range 22
to 542)
- 3 d: 26.2
7 d: 36.7
360 d: 89.6
Fox 2005 mf/20 µL ALB plus
DEC
245 13.4 (95% CI
11.4 to 15.8)
3 months: 2.3
(95% CI 2.0
to 2.7)
6 months:
0.76 (95% CI
0.7 to 0.9)
3 months:
37.3
6 months:
80.4
DEC 246 12.9 (95% CI
11.0 to 15.2)
3 months: 2.9
(95%
CI 2.5 to 3.4)
6 months: 2.8
(95% CI 2.3
to 3.4)
3 months:
31.3
6 months:
50.4
ALB: albendazole; AUC: area under the curve; CFA: circulating filarial antigen; CI: confidence interval; DEC: diethylcarbamazine; IV:
ivermectin; mf: microfilariae.
aOnly in those individuals with over 100 mf/µL blood before treatment, and those examined at baseline, and 3, 6, and 12 months.
bOnly participants positive for mf at baseline.
cChange in group geometric means.
Appendix 6. Antigen density
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Comparison Trial Outcome
measure
Intervention No.
participants
Pretreatment Post-
treatment
% reduction
ALB vs
placebo
Dunyo 2000 CFA unit (ge-
ometric mean
density)
ALB 105 1370 1139 83.1
Placebo 103 1869 2757 147.5 (47.5%
increase)
Fox 2005 CFA unit (ge-
ometric mean
density)
ALB 256 2640 (95% CI
2279 to 3058)
2428 (95% CI
2071 to 2847)
3.2
Placebo 243 2298 (95% CI
1951 to 2706)
2479 (95% CI
2105 to 2919)
1.7
ALB vs IV Dunyo 2000 CFA unit (ge-
ometric mean
density)
ALB 105 1370 1139 83.1
IV 99 1689 1187 70.3
ALB plus IV
vs IV
Dunyo 2000 CFA unit (ge-
ometric mean
density)
ALB plus IV 121 1404 834 59.4
IV 99 1689 1187 70.3
ALB vs DEC Pani 2002a Og4C3 test kit
on 50 µL
serum
ALB 19 0.49 (sd 0.16) 0.08 (sd 0.17) 0.40
DEC 17 0.39 (sd 0.21) 0.07 (sd 0.15) 0.32
Fox 2005 CFA unit (ge-
ometric mean
density)
ALB 256 2640 (95% CI
2279 to 3058)
2428 (95% CI
2071 to 2847)
3.2
DEC 246 2194 (95% CI
1842 to 2613)
1597 (95% CI
1375 to 1855)
17.0
ALB plus
DEC vs DEC
Pani 2002a Og4C3 test kit
on 50 serum
ALB plus
DEC
18 0.47 (sd 0.18) 0.07 (sd 0.15) 0.40
DEC 17 0.39 (sd 0.21) 0.07 (sd 0.15) 0.32
Fox 2005 CFA unit (ge-
ometric mean
density)
ALB plus
DEC
245 2116 (95% CI
1798 to 2490)
1350 (95% CI
1176 to 1549)
26.7
DEC 246 2194 (95% CI
1842 to 2613)
1597 (95% CI
1375 to 1855)
17.0
ALB: albendazole; CFA: circulating filarial antigen; CI: confidence interval; DEC: diethylcarbamazine; IV: ivermectin;mf:microfilariae;
sd: standard deviation.
aMeasured at 360 d.
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Appendix 7. Adult worms
Comparison Trial Outcome mea-
sure
Intervention No. participants Pretreatment Post-treatment
ALB vs DEC Pani 2002 Ultrasonog-
raphy (No. posi-
tive for FDS)
ALB 9 4/9 1 yr: 0/8
2 yr: 0/7
DEC 7 5/7 1 yr: 0/7
2 yr: 0/6
ALB plus DEC
vs DEC
Pani 2002 Ultrasonog-
raphy (No. posi-
tive for FDS)
ALB plus DEC 9 5/9 1 yr: 1/9
2 yr: 1/9
DEC 7 5/7 1 yr: 0/7
2 yr: 0/6
Kshirsagar 2004 Ultrasonogra-
phy
ALB plus DEC 51 35/51 (69%) 3 months: 15/45
(33%)
6 months: 9/46
(20%)
12 months: 15/50
(30%)
DEC 50 30/50 (60%) 3 months: 14/44
(32%)
6 months: 8/45
(18%)
12 months: 15/49
(31%)
ALB: albendazole; DEC: diethylcarbamazine; FDS: filarial dance sign.
Appendix 8. Adverse events
Trial Adverse event Placebo ALB IV ALB plus IV DEC ALB plus
DEC
Dunyo 2000 Tactile fever 1/70 (1.4%) 3/80 (3.8%) 6/66 (9.1%) 16/80
(20.0%)
- -
Headache 0/70 (0%) 1/80 (1.3%) 7/66 (10.6%) 14/80
(17.5%)
- -
Muscle/joint
pain
2/70 (2.9%) 3/80 (3.8%) 9/66 (13.6%) 10/80
(12.5%)
- -
Weakness 1/70 (1.4%) 1/80 (1.3%) 4/66 (6.1%) 7/80 (8.8%) - -
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(Continued)
Abdominal
pain
1/70 (1.4%) 1/80 (1.3%) 0/66 (0%) 4/80 (5%) - -
Diarrhoea 2/70 (2.9%) 0/80 (0%) 1/66 (1.5%) 2/80 (2.5%) - -
Itching 0/70 (0%) 1/80 (1.3%) 2/66 (3.0%) 1/80 (1.3%) - -
Rash 1/70 (1.4%) 0/80 (0%) 1/66 (1.5%) 1/80 (1.3%) - -
Beach 1999
(only partici-
pants mf pos-
itive at base-
line)
Self-reported
fever
7/29 (24%) 5/27 (19%) - - - -
Headache 12/29 (41%) 6/27 (22%) - - - -
Myalgias 3/29 (10%) 3/27 (11%) - - - -
Cough 2/29 (7%) 3/27 (11%) - - - -
Pani 2002 Any ad-
verse reaction
(mainly fever,
headache,
myalgia)
- 42.1% - - 52.9% 61.1%
Mean
intensity score
a (sd)
- 1.8 (3.0) - - 5.6 (7.1) 6.7 (6.6)
Jayakody
1993
Severe scrotal
syndromeb
- 2/15 (13%) - - 0 -
Scro-
tal syndrome:
mild, moder-
ate, or severe
- 11/15 (73%) - - 0 -
Fever, right
hypochon-
drial pain, and
repeated vom-
iting
- 0/15 - - 1/13 (8%) -
Kshirsagar
2004
Total num-
ber of partici-
pants with ad-
verse drug re-
actions by day
5
- - - - 138/693
(20%)
120/702
(17%)
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(Continued)
Total
number of ad-
verse events
- - - - 270 238
Number of
adverse events
thought likely
to be drug re-
lated
- - - - 256 (95%) 221 (93%)
OF LIKELY ADVERSE EVENTS:
CTCc Grade
1
- - - - 144 116
CTCc Grade
2
- - - - 65 57
CTCc Grade
3
- - - - 47 48
CTCc Grade
4
- - - - 0 0
No. of partici-
pants where
adverse events
interfered
with daily ac-
tivities
- - - - 29/693
(4.2%)
31/702
(4.4%)
Fox 2005 SPECIFIC SYMPTOMS
Self-re-
ported or doc-
umented fever
10/43 (23%) 9/46 (20%) - - 16/44 (36%) 25/47 (53%)
(P < 0.05 com-
pared with
ALB)
Headache 12/43 (28%) 11/46 (24%) - - 19/44 (43%) 23/49 (49%)
Myalgias 7/43 (16%) (P
< 0.05 com-
pared with
ALB)
1/46 (2%) - - 8/44 (18%) (P
< 0.05 com-
pared with
ALB)
5/47 (11%)
Cough 7/43 (16%) (P
< 0.05 com-
pared with
ALB)
1/46 (2%) - - 6/44 (14%) 7/47 (15%)
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(Continued)
MEAN TREATMENT IMPACT SCORE (range)d
Day 1 0.79 (0 to 3) 0.76 (0 to 3) - - 1.46 (0 to 3)
(P < 0.05 com-
pared
with ALB and
placebo)
1.66 (0 to 3)
(P < 0.05 com-
pared
with ALB and
placebo)
Day 2 0.49 (0 to 2) 0.26 (0 to 1) - - 0.84 (0 to 3)
(P < 0.05 com-
pared with
ALB)
0.66 (0 to 3)
(P < 0.05 com-
pared with
ALB)
Day 3 0.16 (0 to 1) 0.2 (0 to 2) - - 0.36 (0 to 3) 0.32 (0 to 3)
Day 4 0.16 (0 to 3) 0.07 (0 to 1) - - 0.20 (0 to 3) 0.13 (0 to 1)
Day 5 0.05 (0 to 1) 0.02 (0 to 1) - - 0.11 (0 to 2) 0.06 (0 to 2)
Day 6 0 (0) 0.02 (0 to 1) - - 0.07 (0 to 2) 0.02 (0 to 1)
Day 7 0 (0) 0 (0) - - 0 (0) 0 (0)
aAll systemic adverse reactions recorded by assigning score 0 (none), 1 (mild) 2 (moderate) or 3 (severe).
bMild = epididymis felt enlarged and tender, and spermatic cord was tender and nodular, scrotal sac swollen; moderate = swelling
of scrotal sac, tender epididymis, swelling, nodularity or cord and some systemic features, eg fever malaise; severe = whole scrotal sac
swollen and palpation quite painful, features of acute inflammation eg redness, warmth, pain, swelling, systemic features such as fever,
chills, anorexia, nausea.
cNCI Common Toxicity Criteria grades; Grade 1 = mild adverse event, 2 = moderate adverse event, 3 = severe adverse event, 4 = life-
threatening or disabling adverse event, 5 = death.
d1: symptoms were noticed, but did not interfere with daily activities; 2: symptoms caused some interference with daily activities; 3:
symptoms prevented usual daily activities.
WH A T ’ S N E W
Last assessed as up-to-date: 13 August 2005.
Date Event Description
5 August 2008 Amended Converted to new review format with minor editing.
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H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 1, 2004
Date Event Description
14 August 2005 New search has been performed The first review update, published in Issue 4, 2005, includes three new trials,
Fox 2005, Kshirsagar 2004, and Simonsen 2004, and a two-year update of
results from the Pani 2002 trial.
C O N T R I B U T I O N S O F A U T H O R S
Julia Critchley assessed studies for inclusion, extracted data, and is responsible for preparing and updating the review. Paul Garner
edited the review, extracted data, and assessed the risk of bias in the trials. David Addiss and Hellen Gelband edited the review. Carrol
Gamble edited the review and provided statistical input. Henry Ejere assessed studies for inclusion and extracted data.
D E C L A R A T I O N S O F I N T E R E S T
For the first version of the review (IFRG 2004), Henry Ejere’s salary was paid by The Lymphatic Filariasis Support Centre based
in the Liverpool School of Tropical Medicine. The Department for International Development, UK and GlaxoSmithKline fund the
Lymphatic Filariasis Support Centre. Dr Addiss is an author on one of the trials.
Julia Critchley, Paul Garner, Hellen Gelband, Carrol Gamble: none known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Department for International Development, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The first version of the review (IFRG 2004), published in Issue 1, 2004, deviated from the published protocol: Julia Critchley was
invited to join the review team; the objectives were reworded; and the subgroups were removed from the review methods because they
were no longer appropriate.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Albendazole [∗therapeutic use]; Diethylcarbamazine [therapeutic use]; Drug Therapy, Combination; Elephantiasis, Filarial [∗drug
therapy]; Filaricides [∗therapeutic use]; Ivermectin [therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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